UNIVERSIDADE D
COIMBRA

Inês Martins Penedones

Relatórios de Estágio e Monografia intitulada "Recent advances in nanofibers as potential therapeutic systems: A systematic review" referentes à Unidade Curricular "Estágio", sob a orientação da Dra. Ana Andrade, do Dr. Paulo Monteiro e da Professora Doutora Ana Rita Figueiras, apresentados à Faculdade de Farmácia da Universidade de Coimbra, para apreciação na prestação de provas públicas de Mestrado Integrado em Ciências Farmacêuticas.

Setembro de 2021

UNIVERSIDADE D
COIMBRA

Inês Martins Penedones

Relatórios de Estágio e Monografia intitulada "Recent advances in nanofibers as potential therapeutic systems: A systematic review" referentes à Unidade Curricular "Estágio", sob a orientação da Dra. Ana Andrade, do Dr. Paulo Monteiro e da Professora Doutora Ana Rita Figueiras, apresentados à Faculdade de Farmácia da Universidade de Coimbra, para apreciação na prestação de provas públicas de Mestrado Integrado em Ciências Farmacêuticas.

Setembro de 2021

Declaração de autoria

Eu, Inês Martins Penedones, estudante do Mestrado Integrado em Ciências Farmacêuticas, com o nº 2016240251, declaro assumir toda a responsabilidade pelo conteúdo do Documento Relatório de Estágio e Monografia intitulada "*Recent advances in nanofibers as potential therapeutic systems: A systematic review*" apresentados à Faculdade de Farmácia da Universidade de Coimbra, no âmbito da unidade curricular de Estágio Curricular.

Mais declaro que este Documento é um trabalho original e que toda e qualquer afirmação ou expressão, por mim utilizada, está referenciada na Bibliografia, segundo os critérios bibliográficos legalmente estabelecidos, salvaguardando sempre os Direitos de Autor, à exceção das minhas opiniões pessoais.

Coimbra, 14 de setembro de 2021,

Inês Martins Penedones

(Inês Martins Penedones)

AGRADECIMENTOS

À Owlpharma e equipa, pela confiança depositada em mim. À Dra. Ana Andrade, Dra. Ana Teresa Martins e a toda a equipa do departamento de Assuntos Regulamentares por todo o conhecimento transmitido.

Ao Dr. Paulo Monteiro e a toda a equipa da Farmácia São José, em especial à Dra. Carla Oliveira por me terem acolhido da melhor maneira e pelo profissionalismo demostrado. À minha colega de estágio, Francisca Janeiro, pelo companheirismo.

À Professora Doutora Ana Rita Figueiras, pela disponibilidade e orientação na escrita da monografia.

À Faculdade de Farmácia da Universidade de Coimbra por me ter acolhido durante estes 5 anos e me ter concedido as bases para me tornar numa excelente profissional.

Ao Núcleo de Estudantes de Farmácia da Universidade de Coimbra por me ter dado a oportunidade de crescer pessoal e profissionalmente.

Aos amigos de Coimbra – Bruno, Vina, Mineiro, Tiaguinho, Mariano, Bá e Gui – pela paciência, irreverência e suporte ao longo do meu percurso académico.

Às amigas de Chaves – Babs, Sofs, Ivs e Calejo – porque apesar de distantes estiveram sempre presentes.

Aos meus pais, os proporcionadores deste incrível percurso, sem eles nada disto seria possível. Pelo apoio e pela confiança depositada.

À Mami e ao Papi por acreditarem sempre em mim desde pequenina.

À minha irmã, o meu maior apoio. Por todas as palavras de coragem e pelo enorme suporte ao longo destes 5 anos.

Obrigada a todos!

Índice

Parte I - Relatório de Estágio em Farmácia Comunitária

Parte II - Relatório de Estágio em Indústria Farmacêutica

Parte III - Monografia

Parte I

Relatório de Estágio em Farmácia Comunitária

Farmácia São José

Abreviaturas

CHUC - Centro Hospitalar e Universitário de Coimbra (CHUC)

COVID-19 - Doença por Coronavírus (do inglês, *Coronavirus Disease*)

FFUC - Faculdade de Farmácia da Universidade de Coimbra

FSJ - Farmácia São José (FSJ)

MICF - Mestrado Integrado em Ciências Farmacêuticas

NMA - Novo Módulo de Atendimento (NMA)

SNS - Serviço Nacional de Saúde

SWOT - *Strengths, Weaknesses, Opportunities, Threats*

TRAg - Testes Rápidos de Antigénio

1. Introdução

Segundo as normas presentes no 44.º Artigo da diretiva 2013/55/UE do Parlamento Europeu e do Conselho de 20 de novembro de 2013 [Parlamento Europeu, 2013], e de acordo com as normas orientadoras do estágio curricular para o plano de estudos do Mestrado Integrado em Ciências Farmacêuticas (MICF), o título de Mestre apenas é concedido após a realização de um estágio obrigatório em Farmácia Comunitária.

A relevância do estágio está relacionada com a complementaridade da formação académica, quer teórica quer prática, oferecida pela Faculdade de Farmácia da Universidade de Coimbra (FFUC), estando também relacionada com a aquisição de competências relacionadas com a prática farmacêutica na área de Farmácia Comunitária. Deste modo, a realização do estágio permite a integração dos conhecimentos adquiridos durante o MICF e a consciencialização no contexto profissional, fomentando a aptidão profissional do setor e proporcionando a capacitação do estudante no que toca às necessidades da população, em geral, e do utente, em particular.

Este relatório tem como objetivo descrever as atividades realizadas no decorrer deste estágio curricular, que decorreu no período compreendido de 12 de abril de 2021 a 30 de junho de 2021, sob a orientação do Dr. Paulo Monteiro O relatório irá ser apresentado sob a forma de uma análise SWOT, onde serão explanadas as forças (strengths), as fraquezas (weaknesses), as oportunidades (opportunities) e as ameaças (threats), de forma a analisar o meu percurso e desenvolvimento durante a realização do estágio.

2. Farmácia São José

A Farmácia São José (FSJ) localiza-se na Avenida Calouste Gulbenkian e, como tal, encontra-se envolvida por inúmeras estruturas da área da saúde, como o Centro Hospitalar e Universitário de Coimbra (CHUC), a Maternidade Doutor Bissaya Barreto, o Centro de Saúde de Celas, o Instituto Português de Oncologia de Coimbra Francisco Gentil e inúmeros consultórios médicos privados.

Atendendo à proximidade das estruturas anteriormente referidas e à qualidade da equipa técnica da farmácia, a FSJ apresenta-se com um elevado fluxo de utentes marcados por uma enorme heterogeneidade no que toca à sua literacia e ao poder económico.

Falta ainda referir que a FSJ possui um horário de funcionamento alargado, funcionando semanalmente de segunda a sábado, e assegurando um período de atividade de 24 horas nos dias de serviço permanente.

3. Análise SWOT

De seguida, apresento uma análise referente ao período do meu estágio. Para tal, realizei uma análise SWOT (Strengths, Weaknesses, Opportunities, Threats), uma ferramenta de gestão amplamente conhecida que permite a inclusão e análise de critérios internos e externos.

Na Tabela 1, está presente um resumo da análise em questão, sendo a mesma devidamente aprofundada e fundamentada em seguida.

S	W	O	T
FORÇAS	**FRAQUEZAS**	**OPORTUNIDADES**	**AMEAÇAS**
• Inventário da Farmácia • Divisão da Equipa • Equipamentos tecnológicos • Sentido de Iniciativa e Autonomia	• Número de Estagiários • Férias da Equipa	• Novo módulo de atendimento do Sifarma® • Localização, Horário e Utentes • Realização de TRAg COVID	• Receitas Manuais • Pandemia COVID-19

Tabela 1 - Análise SWOT

3.1 Forças

3.1.1 Inventário da Farmácia

A FSJ possui um elevado número de referências medicamentosas, de dermocosmética, de puericultura, de ortopedia, de veterinária e de suplementação alimentar. Consequentemente, durante o meu período de estágio, foi-me dada a oportunidade de contactar com os inúmeros produtos e de observar os atendimentos da equipa da FSJ, de modo a adquirir informação técnica e científica sobre os produtos dispensados. Este facto permitiu-me consolidar e pôr em prática muitos dos conhecimentos adquiridos ao longo do MICF.

3.1.2 Divisão da Equipa

A equipa técnica da FSJ está dividida em pequenos grupos especializados nas diferentes funções e tarefas que constituem o dia a dia da farmácia. Por exemplo, uma das equipas está direcionada para a parte do atendimento e outra para a parte das encomendas, o que permite que as pessoas que as constituem estejam concentradas em determinadas tarefas dessas áreas.

Considero que este foi um dos pontos positivos do meu estágio, pois deste modo a aprendizagem dos estagiários acaba por ser auxiliada por equipas especializadas e focadas.

3.1.3 Equipamentos Tecnológicos

A FSJ conta com vários equipamentos tecnológicos que auxiliam e melhoram a realização do atendimento. O primeiro equipamento a mencionar é o *robot*, que arruma e armazena os produtos medicamentosos, facilitando esta tarefa e tornando-a menos morosa e permite um atendimento mais diligente. Uma das vantagens da sua utilização prende-se com um melhor aproveitamento do tempo em que é feita a dispensa dos medicamentos, sendo possível esclarecer o utente sobre qualquer dúvida que tenha acerca da terapêutica. O outro equipamento que destaco é a máquina automática de trocos, que também contribui para um atendimento mais rápido e minimiza o erro humano.

3.1.4 Sentido de Iniciativa e Autonomia

Tendo em conta o elevado número de estagiários e a elevada carga de trabalho da equipa da FSJ é fundamental um elevado sentido de iniciativa e autonomia para o sucesso do estágio e também para evitar perturbações no normal funcionamento da farmácia em momentos mais críticos. Posto isto, o grupo de estagiários onde estava inserida procurava realizar várias tarefas de uma maneira crítica e analisando meticulosamente os procedimentos impostos pela FSJ. No entanto, é importante referir que antes de concluir qualquer tarefa, a mesma era revista por um membro da equipa técnica, não deixando espaço para erros, mas sim espaço para crescer.

3.2 Fraquezas

3.2.1 Número de Estagiários

No presente ano letivo, a FSJ aceitou receber 8 estagiários, que foram divididos em duas equipas que estagiaram em dois períodos de 4 meses. Este elevado número de estagiários aliado ao elevado número de colaboradores da equipa da FSJ tornou-se num aspeto menos positivo do meu estágio.

Como referi anteriormente, o elevado número de estagiários permitiu melhorar a minha capacidade de autonomia e responsabilidade. Por outro lado, resultou numa falha de transmissão de alguns conhecimentos e na ausência da realização de determinadas tarefas, como por exemplo a preparação de manipulados. Destaco ainda a dificuldade organizacional durante o período pandémico, uma vez que cumprir as normas de segurança por vezes se tornou complicado.

3.2.2 Férias da equipa

O meu estágio decorreu no período entre abril e julho, que são meses marcados pelas habituais férias de Verão de vários membros da equipa, resultando em algumas lacunas na realização de algumas tarefas. Uma vez que não tinha uma tarefa alocada no trabalho diário da equipa, senti que os estagiários acabaram por colmatar essas baixas na equipa, o que fez com que não tivesse tanta oportunidade de explorar todas as vertentes de Farmácia Comunitária como gostaria, nomeadamente a parte do atendimento.

3.3 Oportunidades

3.3.1 Novo modo de atendimento Sifarma®

Desde outubro de 2020, a FSJ utiliza o Novo Módulo de Atendimento (NMA) em complementaridade com o sistema informático Sifarma 2000®. Ou seja, recorre ao Sifarma 2000® no que toca à receção de encomendas e à gestão de produtos e ao NMA para auxiliar o atendimento. Sendo assim, durante o meu estágio estive em contacto com os dois programas.

Em relação ao NMA, este veio para simplificar diversos procedimentos associados ao atendimento, tornando-os mais intuitivos e rápidos. Tendo em conta que pertenço a uma geração que está bastante habituada a trabalhar com computadores e programas, não foi de todo um problema o uso do NMA. No entanto, é necessário destacar que o NMA ainda contém alguns erros e falta de informação que o Sifarma 2000® fornecia.

3.3.2 Localização, Horário e Utentes

Como já tinha referido anteriormente, a FSJ situa-se numa zona privilegiada no que toca à proximidade a estruturas de saúde, acabando por se tornar numa oportunidade, uma vez que permite uma enorme afluência de pessoas à FSJ. A grande afluência de utentes permite uma maior diversidade de casos e situações clínicas, suscitando uma melhor retenção de conhecimentos e abrangência de temas.

A FSJ tem também um horário de trabalho alargado, o que faz com que seja uma preferência local, uma vez que as farmácias mais próximas terminam o serviço de atendimento mais cedo.

3.3.3 Realização de testes COVID

A situação pandémica levou a que fossem implementadas medidas de obrigatoriedade de apresentação de certificado digital de vacinação, recuperação ou testagem em alguns estabelecimentos ou na realização de algumas atividades. De forma a satisfazer as necessidades da população e tentar controlar a pandemia, a FSJ começou a realizar testes rápidos de

antigénio (TRAg) para a COVID-19. A realização deste serviço por parte da farmácia permitiu-me o contacto com a realidade mais próxima da pandemia e atuar como agente de saúde pública.

3.4 Ameaças

3.4.1 Receitas manuais

Apesar da obrigatoriedade de a prescrição ser feita através de uma receita eletrónica, há exceções que permitem que seja usada a prescrição manual, nomeadamente: falência informática; inadaptação fundamentada do prescritor, previamente confirmada e validada anualmente pela respetiva Ordem Profissional; prescrição no domicílio e até 40 receitas/mês [INFARMED, 2018]. O uso das receitas manuais pode induzir em erro tanto na seleção da substância ativa, como da dosagem, tornando-se um risco para o utente. A compreensão do que é prescrito pode ser morosa ou mesmo impossível, tendo recorrido, em várias situações, ao próprio médico para entender o que vem descrito na receita. Importa também referir que a prescrição manual deve cumprir algumas especificações, como o nome e o número do Serviço Nacional de Saúde (SNS) do utente, que muitas vezes não são compridas, impossibilitando a dispensa ou a comparticipação da medicação.

3.4.2 Pandemia COVID-19

Apesar da pandemia de COVID-19 se ter iniciado há mais de um ano, esta ainda teve um grande impacto no decorrer do meu estágio. Houve a necessidade de reduzir o número de utentes presentes no interior da farmácia, o que originou algumas desvantagens, nomeadamente a diminuição do número de atendimentos em simultâneo.

Como já referido, a FSJ recebe um elevado número de estagiários, o que, aliado ao elevado número de colaboradores da equipa técnica, resulta numa dificuldade na organização do espaço. Acresce ainda mencionar que o período pandémico reduziu o número de formações internas e externas.

4. Casos Práticos

4.1 Caso Clínico 1

S.M., utente do sexo feminino com idade compreendida entre os 20-30 anos, dirige-se à FSJ queixando-se do aparecimento de umas manchas no pé e na zona do tronco. Após analisar o caso, confirmei que eram pequenas borbulhas sem exsudato. Questionei a utente sobre há quanto tempo se tinha apercebido da situação, que respondeu dizendo que na zona do pé há uma semana e na zona do tronco há 4-5 dias. De seguida, questionei se sentia prurido, sendo

que a utente respondeu afirmativamente. De forma a tentar descartar várias situações, questionei se estava a tomar alguma medicação, se tinha mudado algum dos produtos de higiene/hidratação ou usado roupa nova. A utente responde que não a todas as situações questionadas, afirmando que tinha feito uma vida normal sem alterações. Descartando assim a possibilidade de alergia de contacto ou reação adversa a um medicamento, aconselhei a toma de um anti-histamínico, mais concretamente a cetirizina, para aliviar o prurido. Se as borbulhas se mantivessem após uma semana ou se a situação piorasse, aconselhei a utente a consultar um médico.

4.2 Caso Clínico II

L.B., utente do sexo masculino com idade compreendida entre 50-60 anos, dirige-se à FSJ começando por explicar que tem experienciado sangramento nas gengivas, o que lhe tem causado grande desconforto. Afirma que já contactou o seu médico e que o mesmo lhe explicou que seria um efeito secundário de um medicamento que estava a fazer para a hipertensão arterial. Questionei o utente sobre qual o medicamento que estava a fazer e se já o tinha alterado. L.B. responde que não se recorda qual era, mas que o médico já lhe prescreveu um novo e que já tinha iniciado a sua toma e que se tinha dirigido à farmácia para adquirir algo que alivie o desconforto oral.

Sendo assim, aconselhei aplicar Elugel Gel Oral® aquando da higiene oral regular. Questionei ainda que tipo de escova dos dentes costuma usar, na possibilidade de estar a usar uma escova dos dentes com cerdas duras, o que poderia ser um fator que estivesse na base do desconforto. O utente afirma que tem usado uma escova dos dentes dura. Acabei por aconselhar uma escova de dentes com cerdas suaves.

4.3 Caso Clínico III

T.O., utente do sexo feminino, dirige-se à FSJ com uma receita de UL-250® e Dioralyte®, pois tinha tido diarreia. Após consultar a receita, questionei se tinha dúvidas na toma da medicação e a utente responde dizendo que tem alergia à lactose e pede para confirmar se a medicação que ia fazer continha essa substância. Pesquisei no Infomed o Resumo das Características do Medicamento do UL-250® e verifiquei que este contém lactose mono-hidratada. Ao saber disto, a utente pede uma alternativa, afirmando que é algo recorrente uma vez que a maioria dos medicamentos contém lactose na sua constituição. Verifiquei em produtos como Atyflor® e Advancis BacilPro® e todos continham lactose. Por fim, analisei o produto Probify® e confirmei que não contém lactose e que a maioria das estirpes presentes no UL-250® também se encontram neste produto.

5. Conclusão

No decorrer do meu estágio curricular na FSJ, tive a oportunidade de aplicar os conhecimentos teóricos obtidos ao longo do meu percurso académico e entrei em contacto com novas áreas de aprendizagem, possibilitando a aquisição de valências e competências fundamentais para a minha futura vida profissional.

Na maioria das vezes, a farmácia é um ponto primário ao qual a população se desloca para tentar esclarecer problemas ou dúvidas nas mais diversas situações, sendo que esta recorrência aumentou com a pandemia. As interações entre o farmacêutico e utente são de grande importância para um aconselhamento completo e personalizado, sendo também fundamentais para ganhar a confiança da população na Farmácia Comunitária. Sem dúvida que isto foi algo que aprendi no decorrer o meu estágio: a ouvir e entender os problemas da população e tentar dar o melhor e mais personalizado aconselhamento.

Resta-me agradecer a toda equipa pela paciência e por todos os conhecimentos que me transmitiu ao longo do meu estágio. Para mim, foi uma honra poder ter integrado esta excelente equipa.

Bibliografia

Parlamento Europeu e Conselho da União Europeia. Diretiva 2013/55/UE do Parlamento Europeu e do Conselho de 20 de novembro de 2013. Jornal Oficial da União Europeia. (Consultado a 20 de agosto de 2021). Disponível em: https://eur-lex.europa.eu/legal-content/PT/TXT/PDF/?uri=CELEX:32013L0055&from=DA

INFARMED, Normas relativas à prescrição de medicamentos e produtos de saúde, 18 de abril de 2018. (Consultado a 30 de agosto de 2021). Disponível em: https://www.infarmed.pt/documents/15786/17838/Normas_Prescri%FF%FF%FF%FFo/bcd0b378-3b00-4ee0-9104-28d0db0b7872?version=1.3&previewFileIndex=

Parte II

Relatório de Estágio em Indústria Farmacêutica

OWLPHARMA - CONSULTING, LDA.

Abreviaturas

AIM - Autorização de Introdução no Mercado

ARM - Assuntos Regulamentares do Medicamento

CMC - *Chemistry, Manufacturing and Control*

COVID-19 - Doença por Coronavírus (do inglês, *Coronavirus Disease*)

CTD - *Common Technical Document*

EDQM - *European Directorate for the Quality of Medicines*

EMA - *European Medicines Agency*

EuCSI - *European Core Safety Information*

FFUC - Faculdade de Farmácia da Universidade de Coimbra

FI – Folheto Informativo

INFARMED - Autoridade Nacional do Medicamento e Produtos de Saúde

MedDRA - *Medical Dictionary for Regulatory Activities*

MICF - Mestrado Integrado em Ciências Farmacêuticas

QRD - *Quality Review of Documents*

RCM - Resumo das Características do Medicamento

SWOT - *Strengths, Weaknesses, Opportunities, Threats*

1. Introdução

Com o término do plano de estudos do Mestrado Integrado em Ciências Farmacêuticas (MICF) na Faculdade de Farmácia da Universidade de Coimbra (FFUC) é obrigatória a realização de um estágio curricular, de forma a adaptar os futuros farmacêuticos ao variadíssimo mercado de trabalho que têm à sua disposição.

Esta instituição de ensino dá aos seus estudantes a oportunidade de realizarem um estágio curricular noutra área profissional farmacêutica para além de Farmácia Comunitária e/ou Farmácia Hospitalar. A FFUC disponibiliza uma ampla gama de estágios já pré-acordados com diversas entidades, nomeadamente na área da Indústria Farmacêutica, na área regulamentar, na área das análises clínicas, na área da distribuição, entre outras.

No decorrer do meu percurso académico, notei que houve da minha parte um crescente interesse pela área da Indústria Farmacêutica e, com a unidade curricular de Assuntos Regulamentares do Medicamento (ARM), surgiu uma nítida preferência pela área regulamentar. Tendo isto em consideração e aproveitando a possibilidade de poder realizar um estágio curricular nessa área, optei pela consultora farmacêutica Owlpharma – Consulting, Lda., que se apresenta como uma empresa especializada em Assuntos Regulamentares, Farmacovigilância, Garantia de Qualidade e Assuntos Médicos e Científicos.

Este relatório tem como objetivo descrever as atividades realizadas neste estágio curricular, que decorreu no período compreendido de 11 de janeiro de 2021 a 9 de abril de 2021, sob a orientação da Dra. Ana Andrade. O relatório irá ser apresentado sob a forma de uma análise SWOT, onde serão explanadas as forças (*strengths*), as fraquezas (weaknesses), as oportunidades (*opportunities*) e as ameaças (*threats*), de forma a analisar o meu percurso e desenvolvimento durante a realização do estágio.

2. Owlpharma – Consulting, LDA.

A *Owlpharma, Consulting*, Lda. é uma empresa de consultoria especializada no setor farmacêutico com principal ação nas áreas de Farmacovigilância, Assuntos Regulamentares, Garantia de Qualidade e Assuntos Médicos e Científicos.

A empresa foi criada no ano de 2013 e encontra-se sediada em Coimbra. Desde a sua fundação, a Owlpharma é uma referência na área de consultoria, contando já com três prémios "Gazela", prémio que distingue empresas com um crescimento exponencial. Posto isto, a Owlpharma realiza serviços especializados que abrangem todo o ciclo de vida do

medicamento, estando sempre articulada com as agências regulamentares, tanto a nível nacional como internacional e considerando sempre a legislação em vigor [Owlpharma, 2021].

Durante o meu estágio, tive a oportunidade de integrar o Departamento de Assuntos Regulamentares desta empresa.

3. Análise SWOT

De seguida, apresento uma análise referente ao período do meu estágio. Para tal, realizei uma análise SWOT (*Strengths, Weaknesses, Opportunities, Threats*), uma ferramenta de gestão amplamente conhecida que permite a inclusão e análise de critérios internos e externos.

Na Tabela 1, está presente um resumo da análise em questão, sendo a mesma devidamente aprofundada e fundamentada em seguida.



Tabela 2 - Análise SWOT

3.1 Forças

3.1.1 Formações

De forma a terem os profissionais mais capazes nas suas funções diárias e estarem sempre atualizados, a Owlpharma dispõe de várias formações nas respetivas áreas de atuação. Essas formações também são disponibilizadas aos estagiários, o que acaba por facilitar a sua integração na equipa e dar uma maior perceção sobre a dinâmica do trabalho a realizar.

- Durante o período de estágio, realizei as seguintes formações:
- Alterações aos termos da Autorização de Introdução no Mercado (AIM);

- Preparação de Módulo 3 de dossiers em formato *Common Technical Document* (CTD);
- Publicidade de Medicamentos;
- Produtos cosméticos e de higiene corporal.

Com estas formações, foi possível ter uma melhor perceção não só das tarefas que posteriormente vim a realizar, mas também de outras atividades que são da responsabilidade do departamento de Assuntos Regulamentares.

3.1.2 Autonomia e responsabilidade

Durante o meu estágio, senti que me foi depositada confiança na realização das múltiplas tarefas, o que acabou por se traduzir numa forma de trabalho mais autónoma. Quando me era delegada uma tarefa, eram também transmitidas as orientações necessárias sobre a mesma, sendo também possível tirar qualquer dúvida que surgisse. Aquando da realização da tarefa, era-me concedida total liberdade na sua realização, o que me permitiu estimular a minha capacidade de organização e gestão de prazos. No entanto, apesar da confiança demostrada, o trabalho realizado era sempre verificado por outrem de forma a garantir um elevado rigor no trabalho apresentado aos clientes. O *feedback* que me era dado após a verificação dos mesmos, incentivou a que houvesse um aperfeiçoamento e uma melhoria contínua dos meus resultados.

3.1.3 Diversidades de tarefas

Apesar de só ter estado alocada a um departamento, foram-me atribuídas inúmeras tarefas que se destacavam pela sua diversidade, permitindo-me assim contactar com a realidade praticada no dia a dia de um departamento de Assuntos Regulamentares.

Das tarefas que me foram delegadas, posso destacas as seguintes:

- Comparação de Resumos das Características do Medicamento (RCM) aprovados com *European Core Safety Information* (EuCSI);
- Elaboração de Resumos da Características do Medicamento, Folhetos Informativos (FI) e Rotulagens, segundo o formato *Quality Review of Documents* (QRD), através de traduções de português para inglês ou vice-versa;
- Preparação e submissão de Alterações de AIM, através da plataforma online do INFARMED (SMUH-Alter);
- Colaboração na realização de *Bridging Reports*;

- Apoio na realização de um teste de legibilidade.

3.2 Fraquezas

3.2.1 Teletrabalho

Devido à pandemia de COVID-19, no período do meu estágio, foi imposto teletrabalho obrigatório, pelo que o meu estágio foi realizado integralmente de forma remota. Tendo em conta que era o meu primeiro contacto com esta área, muitas vezes surgiam dúvidas que, devido à distância, não eram fáceis de esclarecer. No entanto, devido à equipa sempre acessível e disposta a ajudar, foram-me tiradas todas as dúvidas.

3.2.2 Não realizar tarefas nos outros departamentos

A Owlpharma é uma empresa de consultoria que engloba quatro vertentes do setor farmacêutico. No entanto, só me foi dada a oportunidade de participar no trabalho do departamento de Assuntos Regulamentares. Teria sido uma oportunidade de aumentar os meus conhecimentos nas outras áreas, mas tendo em conta que o estágio apenas tem apenas a duração de três meses, também não seria muito vantajoso estar a mudar de departamento e não consolidar o meu conhecimento em apenas um.

3.3 Oportunidades

3.3.1 Plataformas da Área Farmacêutica

A área de Assuntos Regulamentares utiliza plataformas/bases de dados/*websites* específicos do setor farmacêutico. No decorrer do meu estágio, foi-me dada a oportunidade de acesso e utilização regular desse tipo programas, nomeadamente da plataforma SMUH-Alter, que é utilizada para a submissão de alterações de AIM, do *Medical Dictionary for Regulatory Activities* (MedDRA) e do *European Directorate for the Quality of Medicines* (EDQM), para consultar os termos e estar sempre atualizada na informação a utilizar no meu trabalho.

Também me foram dadas bases e *background* de pesquisa em *websites*, como o da EMA e Infomed.

3.3.2 Melhoria das competências pessoais

É notória a exigência de organização, resolução de problemas, trabalho em equipa e pensamento crítico na Área Regulamentar. Este estágio permitiu-me desenvolver essas *soft skills* que me farão ser uma melhor profissional no futuro.

Aliado a estes fatores, é também importante a competência linguística. Uma vez que o inglês é considerado a língua universal e a internacionalização das indústrias farmacêuticas é cada vez mais notória, o contacto diário com a língua permitiu uma melhoria considerável.

3.4 Ameaças

3.4.1 Plano de Estudos

No que toca especificamente ao meu estágio no departamento de Assuntos Regulamentares, o MICF oferece duas unidades curriculares que abordam esta grande saída profissional, sendo uma delas opcional (Gestão de Processos Regulamentares). Considero que estas duas unidades curriculares apenas nos concedem o mínimo de conhecimentos para exercer este tipo de funções, o que nos pode deixar muitos receosos e incapazes de embarcar neste caminho.

De referir que, neste momento, o MICF continua muito centrado na área de Farmácia Comunitária, havendo ainda outras áreas emergentes por explorar e aprofundar, como por exemplo, Assuntos Regulamentares e os seus ramos (Pré-AIM, Pós-AIM, CMC), Marketing, *Market Acess*, Farmacoeconomia, entre outras.

4. Conclusão

O estágio curricular que realizei na Owlpharma, Consulting Lda. permitiu-me entrar em contacto com uma das saídas profissionais que mais me chamou a atenção no decorrer do MICF. A parte regulamentar despertou o meu interesse após ter contactado com a unidade curricular de ARM e esta experiência veio aumentar ainda mais o meu interesse.

Pude integrar um departamento onde não possuía muitos conhecimentos e, consequentemente, consegui evoluir e crescer tanto a nível pessoal como a nível profissional. Assim sendo, este estágio permitiu consolidar conhecimentos teóricos que obtive na faculdade e enriquecer-me a nível formativo em novos assuntos, levando comigo conhecimentos e práticas que, decerto, farão de mim uma melhor profissional.

Resta-me agradecer a toda a equipa que me acolheu durante o meu estágio por todo o conhecimento transmitido e por se mostrarem sempre disponíveis para me ajudar a superar qualquer dificuldade.

Bibliografia

OWLPHARMA - Owlpharma - Consulting, Lda. (2021). [Consult. 19 jul. 2021]. Disponível em: https://www.owlpharma.pt/

Parte III

Monografia

Recent advances in nanofibers as potential therapeutic systems: A systematic review

Abbreviations

AgNPs - Silver Nanoparticles

AIDS - Acquired Immunodeficiency Syndrome

BC - Benzalkonium Chloride

bFGF - Basic Fibroblast Development Factor

DCA - Dichloroacetate

DNA - Deoxyribonucleic Acid

DOX - Doxorubicin

DSC - Differential Scanning Calorimetry

ECM - Extracellular Matrix

EGF - Epidermal Development Factor

HIV - Human Immunodeficiency Infection

MADO - poly(dopamine methacrylamide-co-methyl methacrylate)

PBELA - Poly(benzaldehyde-poly (ethylene glycol))- poly(D,L-lactide)

PCL - Poly ε-caprolactone

PDGF-BB - Platelet-inferred Development Factor-BB

PEG-PLLA - Poly(ethylene glycol)-poly(L-lactic acid)

PEO - polyethylene oxide

PGA - Poly Glycolic Acid

PHBV - 3-hydroxybutyrate-co-3-hydroxyvalerate

PLA - Poly(lactic acid)

PLGA - Poly Lactic-co-glycolic acid

PLLA - Poly(L-lactic acid)

PTX - Paclitaxel

PU - Ployurethan

PVA - Poly-vinyl-alcohol

PVP - Polyvinyl Pyrrolidone

RH - Relative Humidity

RNA - Ribonucleic Acid

SHCC - Singular Hepatocellular Carcinoma

VEGF - Vascular Endothelial Development Factor

Abstract

The fast advancement in nanotechnology has prompted the improvement of numerous methods for the creation of various nanoscale composites of which nanofibers have gotten extensive consideration. Nanofibers are solid fibres of materials, which have a diameter under a micrometre. They vary in porous structure and have an extremely extensive area. Material choice is of crucial importance for the assembly of nanofibers and their interaction with cells, which leads to bound tissue responses. Therefore, artificial, or natural materials will be chosen to support their compatibility with the biological surroundings. Among the different known methods for nanofiber creation, electrospinning is the most utilized because of its simplicity. Active pharmaceutical ingredients can be joined within the nanofiber network, adsorbed, or artificially bounded to the nanofiber surface. A broad scope of useful mixtures, including drugs (antibiotics, anticancer medications), proteins, peptides, compounds, cells, DNA/RNA, can be conveyed through nanofibers. Hence, research on biomedical applications for nanofibers has zeroed in on cancer therapy, scaffolds for tissue engineering, wound dressing, dementia/diabetes/AIDS. Although nanofibers have shown incredible potential for drug conveyance applications. There are difficulties which should be dodged before they can be utilized as medication conveyance vehicles. This review intends to give an outline of the recent advances in nanofibers, contemplating the preparation methods, the drug loading and release and the various therapeutic applications.

Keywords: Nanotechnology, Nanofibers, Electrospinning, Drug loading, Therapeutic Applications.

Resumo

O rápido avanço da nanotecnologia levou ao aprimoramento de métodos envolvidos na criação de compostos em nanoescala, dos quais as nanofibras receberam um grande destaque. Nanofibras são fibras que têm um diâmetro inferior a um micrómetro, variam em estrutura e possuem uma área extensa. A escolha do material que constitui a nanofibra é de grande importância para a sua produção e interação com as células. Portanto, polímeros naturais ou sintéticos serão escolhidos de forma a suportar a compatibilidade com o meio biológico a que são expostos. De entre os diferentes métodos conhecidos para a produção de nanofibras, o *electrospinning* é o mais utilizado devido à sua simplicidade. As substâncias ativas podem ser incorporadas nas nanofibras através da incorporação nas redes de fibras, adsorção, ou ligadas artificialmente à superfície da nanofibra. Vários compostos podem ser transportados através de nanofibras até ao seu alvo terapêutico, incluindo fármacos (antibióticos, antineoplásicos), proteínas, peptídeos, células, ADN/ARN. Consequentemente, a investigação em aplicações biomédicas concentrou-se na terapêutica antineoplásica, engenharia de tecidos, demência, diabetes e SIDA. Embora as nanofibras tenham mostrado potencial para aplicações de fármacos, ainda existem dificuldades que devem ser ultrapassadas antes que possam ser utilizadas como forma farmacêutica. Este trabalho pretende fornecer um esboço dos avanços recentes em nanofibras, contemplando os métodos de preparação, a incorporação e libertação do fármaco e as diversas aplicações terapêuticas.

Palavras-Chave: Nanotecnologia, Nanofibras, *Electrospinning*, Incorporação do Fármaco, Aplicações Terapêuticas.

1. Introduction

Ideal drug delivery systems have been created to accomplish the best restorative impacts and the most minimal toxicity issues [Pant *et al*., 2019]. The fast progress in the area of nanotechnology has led to the increase of numerous methods for the creation of various nanoscale composites [Haider *et al*., 2018; Huang *et al*., 2019], of which nanofibers have been in the spotlight [Zandi *et al*., 2020] because of the variety in the manufacture innovations and applications [Ibrahim *et al*., 2019], particularly in the fields of drug delivery [Kim *et al* 2004], biomedical applications including wound dressing [Unalan *et al*., 2019], and tissue designing [Son *et al*., 2014].

Nanofibers can be manufactured from natural polymers (e.g., chitosan, fibronectin, gelatin, collagen, silk) just as artificial polymers (e.g., poly lactic acid (PLA), poly glycolic acid (PGA), poly lactic-co-glycolic acid (PLGA)), or their different mixes. Fiber mats have been observed to be extremely productive for the conveyance of both hydrophobic and hydrophilic medications. Different parameters that adjust drug release from the fiber mats include medication to polymer proportion, fiber measurement, morphology, or potentially porosity. The functionalization of the nanofibers (e.g surface unite polymerization) is one more methodology used to control drug discharge [Kamble *et al*., 2017].

Electrospinning has been considered as perhaps the most productive technique utilized for the combination of nanomaterials since the 20th century, and extraordinary works have been done in the last part of the 1990s and early of the 21st century [Xue *et al*., 2019]. Aside from electrospinning, there are other non-electro nanofiber procedures, for example, template-based synthesis, phase separation, self-assembly method, melt blown airbrush spray have been investigated by specialists for nanofiber preparation. These procedures give new advances in the field of nanofiber arrangement and are solid contenders of electrospinning strategy offering a few benefits and limits [Thakkar *et al*., 2017].

This review plans to give an outline of the recent advances in nanofibers, as the preparation method, the drug loading and release and the various therapeutic applications.

2. Definition, structure, and composition

Nanofibers are fibres that have a diameter of under a micrometre; they can vary in porous structure and have an extensive area [Frenot and Chronakis *et al*.,2003; Zhang and Yu *et al.,* 2014]. They can be classified in line with their internal structure as uniform or core–

shell nanofibers; or by their orientation as randomly-oriented or aligned nanofibers (Figure 1) [Cai and Heilshorn., 2014; Hu *et al*., 2014].



Figure 1 - Types of nanofibers: (1) uniform and (1') core–shell nanofiber; and (2) randomly-oriented and (2') aligned nanofibers. [Adapted from Pelipenko et al., 2015a]

Nanofibers used in medicine applications should be biocompatible. Biodegradability is a plus feature. The perfect biomaterial is not solely biocompatible and perishable; it should also be nontoxic, moderately deliquescent, and have acceptable mechanical strength [Guimaraes *et al*., 2010].

The nanofibers are tested to be better economic systems for cellular and molecular applications than their micro- or macro-scale counterparts because of their purposeful properties. These properties include a giant area, a higher ratio, superior surface properties, quantum confinement effects, and fast-absorbing ability of biomolecules, which provide rife binding sites for cell receptors; and, subsequently, permit a robust cell-matrix interaction to take place as engineering cells, tissues, and organs [Yang *et al*., 2005].

Material choice is of crucial importance for the assembly of nanofibers and their interaction with cells, which leads to bound tissue responses. Therefore, artificial, or natural materials will be chosen to support their compatibility with the biological surroundings [Beachley and Wen, 2010]. Selection of the correct choice of composite depends on the applications' positioning, and their use [Ito *et al*., 2005]. Nanofibers can be synthesized from natural polymers (e.g., chitosan, fibronectin, gelatin, collagen, silk). Furthermore, they can also be produced by artificial polymers - e.g., PLA, PGA, PLGA, tyrosine-derived polycarbonates, poly ε-caprolactone (PCL), ploy urethan (PU), polyvinyl pyrrolidone (PVP), poly-vinyl-alcohol (PVA), or their varied mixtures [Xu *et al*., 2011; Song *et al*., 2012]. For example, ceramic-polymer nanofiber composites could also be an alternative for osteogenic applications since inorganic–organic materials play a serious role in bone tissue organization. As an example,

HAp/poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) nanofiber composites are used for bone regeneration. On the opposite hand, polymer–polymer nanofiber composites are used in soft tissue regeneration, like skin or viscus. [Ito *et al*., 2005]

Additionally, mixtures of various polymers will be used to prepare nanofibrillar tissue scaffolds that do not trigger the host immune system; to preserve structural integrity, and to confirm a cell-friendly microenvironment [Kriegel *et al*., 2009].

3. Preparation methods

A variety of techniques have been created to prepare nanofibers as portrayed in Figure 2.

Template-based synthesis utilizes nanoporous layers that are financially accessible layouts to incorporate or expel nanoscale strands in the scope of a few hundred nanometre (nm) [Martin *et al*., 1996].

Whereas the separation method phase produces nanofibrous films directly after freezing the drying polymeric mix. This technique is exceptionally dreary and tedious. The strands obtained by this technique are in the scope of 50-500 nm, or smaller length [Ma *et al*., 1999].

The self-assembly method, as the name proposes, includes a cycle wherein the nuclear and atomic totals combine themselves by holding into stable and clear-cut elements at meso or nano measurements. Even though this technique has a longer necessary planning time hindrance, it produces nanofibers in the scope of 100 nm [Hartgerink *et al*., 2001].

Melted blown strategy depends on soften blowing fiber turning innovation. Here, the polymer mix is expelled through a little opening with high-speed floods of warmed air. With this technique, nanofibers strands in the scope of 150-1000 nm [Hassan *et al*., 2013].

Airbrush Spray is another minimal expense, quick and effectively versatile strategy to make nonwoven miniature/nanofibrous layers [Tutak *et al*., 2013]. It is utilized electrospinning strategies for the fabrication process, electrical charge is applied to the soften polymer or solution when it expels out from the needle or pipette or nozzle and the subsequent strands are gathered on an aluminium paper attributable to the attractive forces that are produced because of oppositely charged polymers [Reneker *et al*., 1996].

Electrospinning is the most satisfactory technique for preparing nanofibers and it is explained in more depth below.



Figure 2 - Methods for preparation of nanofibers [Adapted from Kamble et al., 2017]

3.1 Electrospinning

Among the different known methods for nanofiber preparation, electrospinning is the most utilized because of its simplicity. It has drawn in colossal research and business interest because of its flexibility and special ability to deliver dry novel nanomaterials with controllable morphology and stacking limit in a single step [Szentivanyi *et al.*, 2011].

A regular electrospinning arrangement, displayed in Figure 3, comprises three fundamental segments: a needle fitted with a metal nozzle, a high voltage supply, and a collector.

Polymer solution or soften is placed into a needle and mounted on a siphon, which delivers a steady stream rate. To prepare nanofibers a high voltage is associated with the finish of the nozzle. At a low voltage the polymer preparation dribbles from the nozzle. At the point when the electric field arrives at a specific limit, the hemispherical surface of the fluid toward the finish of the nozzle expands and makes a tapered shape known as a Taylor cone. By further expanding the electric field, the basic worth at which the electrostatic power beats the surface pressure is reached, and the charged stream spurts out of the finish of the Taylor cone towards the grounded authority. The jet is consistently protracted and whipped, bringing about a

decrease from a few hundred micrometers to just many nm. At the same time, the jet diminishing permits quick dissolvable vanishing or hardening of the polymer soften to frame strong nanofibers kept on the collector. A standard electrospinning framework is straightforward as far as equipment yet the material science administering the interaction is complex. Up to now, little has been thought about the component of the jet insecurities and the event of the spreading system of the essential stream, bringing about various fibers causing inhomogeneous nanofiber breadths [Reneker *et al.*, 2000; Wang *et al.*, 2009].

Although essential electrospinning is simple, the interaction is influenced by a wide range of boundaries, making electrospinning difficult to work with. As per current information, the boundaries influencing electrospinning can be partitioned into three significant gatherings: solution parameters, process parameters, and ambient parameters [Bhardwaj and Kundu, 2010; Kriegel *et al.*, 2009; Liu *et al.*, 2013; Pelipenko *et al.*, 2012; Tripatanasuwan *et al.*, 2007].



Figure 3 - Schematic electrospinning setup [Adapted from Pelipenko et al., 2015a]

3.1.1 Solution parameters

- **Polymer characteristics**

Polymer type significantly affects between and intramolecular cooperations reflected in the actual properties of arrangement [Gupta *et al.*, 2005]. Polymers with high atomic loads (higher levels of polymerization) are best for electrospinning to empower an adequate number of intermolecular entanglements. In any case, it has been seen that high molecular loads are not generally fundamental for nanofiber development if the snares between polymers are supplanted by adequate intermolecular collaborations (e.g., fourfold hydrogen holding) [McKee *et al.*, 2006]. Typically, arrangements of low molecular weight polymers will frame dots instead of filaments. Expanding the molecular load of a polymer brings about a decrease

in the quantity of beads in the electrospun item [Geng *et al*., 2005; Gupta *et al*., 2005; Haghi and Akbari, 2007]. Moreover, electrospinning has better outcomes when straight polymers are utilized rather than nonlinear polymers, on the grounds that the last structure exceptionally viscous solutions or even gels as of now at low polymer fixations [McKee *et al*., 2004; Rošic *et al*., 2012]. At last, polymers with a polyelectrolyte nature are truly challenging to electrospun [Rošic *et al*., 2012] and accordingly uncharged are best. Polyelectrolytes are additionally inclined to escalated expanding, which prompts exceptionally thick arrangements as of now at low focuses. Furthermore, the polyelectrolyte idea of polymers causes exceptional ghastly powers during electrospinning, which bring about jet instability [Rošic et al., 2012].

- **Polymer concentration**

Polymer concentration, which likewise intently associates with arrangement consistency, is the most generally explored parameter. As per the writing, there is no broad guideline for choosing the ideal polymer concentration since it relies upon polymer and dissolvable qualities.

With a low polymer concentration solution, it is usual to appear irregular beaded filaments and extended globules. By steadily expanding the polymer focus, nonstop filaments show up. Polymer entanglement was recognized as a key factor influencing the progress from short fiber morphology through extended dabs to persistent nanofibers with a smooth surface. The haphazardly appropriated short nanofibers on the gatherer, show fracture, which has happened during plane whipping prior to arriving at the collector. In addition, a higher solution concentration it's confirmed to cause an expansion in the fiber width, which can be clarified by the higher number of traps between polymer chains, restricting plane extending under the applied electric field [Cramariuc *et al*., 2013; Son *et al*., 2004; Veleirinho *et al*., 2008; Zeng *et al*., 2003].

- **Surface tension**

Surface tension is the contractive inclination of a fluid surface that opposes change because of outside power and relies upon the qualities of the dissolvable and solute. Surface pressure unquestionably meddles with the electrospinning system, since it is the principal power acting against Taylor cone arrangement and further jet stretching. Generally, low surface pressure values bring about the arrangement of strands without dots and low voltages can be applied in electrospinning. Surface strain can be controlled by the expansion of surface-

dynamic substances. In any case, a low surface strain can't tackle issues that happen because of too low molecular load of polymer utilized [Bhardwaj and Kundu, 2010].

- **Bulk and interfacial rheological characteristics**

Rheological attributes of polymeric arrangements unequivocally influence electrospinning practicality. It has been demonstrated that an expansion in arrangement thickness results in the development of thicker filaments and less bead generation [Huang *et al*., 2001; Zhao *et al*., 2005], though electrospinning a polymer arrangement with low consistency doesn't empower arrangement of persistent fibers. Not just consistency yet additionally the viscoelastic properties of a polymer arrangement incredibly influence jet development and its steadiness, and in this way nanofiber morphology overall [Rošic *et al*., 2012]. The versatility ought to be a lot lower than the plan to forestall jet separation and bead development, yet present to empower jet initiation. The elastic power builds the propensity of the jet to contract, which forestalls stream commencement and elongation, and prompts fly separation and bead arrangement. Adequate versatility guarantees that the polymer chains in the electrospun jet don't change their adaptation and stay extended during the dissolvable vanishing time [Pelipenko *et al*., 2013b].

Interfacial rheological attributes join classical rheological qualities with surface pressure, hence bringing about a significant prescient instrument for nanofiber arrangement. A further benefit of interfacial rheology over old style rheology is that it inspects the interface with adequate affectability and limits adjustment of the interfacial design while forestalling any adjustment of the conduct of more profound layers [Pelipenko *et al*., 2012]. However, rheological boundaries in mass and at the interface should be concentrated reciprocally. Mass properties are generally dictated by polymer fixation and are subsequently valuable for anticipating plane and fiber development, while the interfacial properties empower the forecast of jet continuation.

- **Conductivity**

Conductivity has been accounted in the literature as a significant solution factor for the electrospinning system. Polymer solutions with low conductivity can't be electrospun because of the shortfall of a surface charge on the liquid drop, which is required for Taylor cone development. Then again, extremely high conductivity prompts a drained unrelated electric field along the outside of the liquid drop, forestalling Taylor cone arrangement [Angammana and Jayaram, 2011]. Because of uncharged polymers, the issue of low conductivity can be

addressed by adding salts, which can be utilized for nanofiber width control. It has been accounted for that higher arrangement conductivities for the most part bring about more slender nanofibers [Angammana and Jayaram, 2011; Cramariuc *et al*., 2013; Zeng *et al*., 2003]. Moreover, the high arrangement conductivity empowers the utilization of lower applied voltage; in any case, profoundly conductive arrangements can be truly unsound in the applied electric field [Bhardwaj and Kundu, 2010].

- **Dielectric constant**

The dielectric steady and its impact on nanofiber morphology have been investigated distinctly in a few studies. It not really settled that effective electrospinning happens when solvents with high dielectric constants are utilized [Jarusuwannapoom *et al*., 2005; Pham *et al*., 2006], coming about additionally in slenderer nanofiber arrangement [Son *et al*., 2004].

3.1.2 Process parameters

- **Applied voltage**

The impact of applied voltage on the result of electrospinning has been portrayed. Voltages somewhere in the range of 5 and 40 kV are typically utilized. Arrangements with low conductivity, high surface strain, as well as high consistency require higher voltages, and the other way around. A high voltage causes expanded unpleasant electrostatic powers, which lead to more broad extending of the electrospun stream, bringing about slenderer fibers [Cramariuc *et al*., 2013; Pham *et al*., 2006]. At the point when applied voltage is too high the likelihood of dab arrangement in the electrospun item is a lot more noteworthy because of Taylor cone flimsiness [Megelski *et al*., 2002; Pham *et al*., 2006].

- **Nozzle tip-to-collector distance**

The distance between nozzle tip and collector was analysed as one of the potential ways to control the diameter of the fiber; its impact has not been demonstrated to be critical [Bhardwaj and Kundu, 2010]. It has been tracked down that an insignificant distance that guarantees adequate time for an electrospun jet to dry prior to arriving at the collector is required. If the distance is too short, the stream doesn't cement before it arrives at the collector which results in nanofiber combination and polymer film development. Expanding the distance brings to a creation of more slender nanofibers [Bhardwaj and Kundu, 2010]. An increment in the spout tip-to-gatherer distance brings about a higher likelihood of dot development [Geng *et al*., 2005; Ki *et al*., 2005].

- **Flow rate**

Command over the solution stream rate relies fundamentally upon the instability of the dissolvable utilized. At the point when the polymer is broken up in an exceptionally unstable dissolvable, higher stream rates ought to be utilized. Notwithstanding, a high stream rate should be joined by a sufficiently high applied electric field to guarantee the electrically prompted extraction of the polymer solution from the nozzle tip as depicted previously.

A few reports show that an expansion in the stream rate prompts development of thicker nanofibers because of thicker jet definition [Bhardwaj and Kundu, 2010; Cramariuc *et al*., 2013; Pham *et al*., 2006]; notwithstanding, high stream rates might result in beads [Bhardwaj and Kundu, 2010] or testimony of undried nanofibers [Pham *et al*., 2006].

- **Nozzle design**

Numerous alterations of turning nozzle have been made for delivering various types of nanofibers [Jiang *et al*., 2014a; Yu *et al*., 2013a]. A solitary channel nozzle permits arrangement of uniform nanofibers, though a coaxial spout empowers development of center shell or even diverse nanofibers. The coaxial nozzle is developed from at least two concentric needles put inside one another [Maleki *et al*., 2013]. As a rule, the internal spout distance across is an essential boundary influencing the thickness of created electrospun filaments. An extreme form of an expanded number of jets is needleless electrospinning, in which different jets show up from the polymer solution surface. This offers the possibility to create nanofibers at an industrial scale [Yarin and Zussman, 2004].

Electrospinning by single-channel nozzle produces uniform nanofibers from a polymer solution or polymer mix [Hu *et al*., 2014]. Because of electrospinning through a coaxial nozzle, the two polymer solutions stream independently through singular channels of the nozzle and don't come in contact until they arrive at the finish of the nozzle, where the nanofiber development begins. By changing the fluid stream rates and applied voltage, center shell strands can be acquired. The polymers utilized decide the center and shell properties of such nanofibers. Coaxial electrospinning isn't restricted distinctly to the creation of nanofibers with a different center and shell, yet additionally permits the dispersion of at least one dynamic segment independently in one or the two pieces of such nanofibers [Wang *et al*., 2009].

- **Collector**

The collector can be a conductive level surface (continuous or designed), a pivoting chamber, or a wheel-like circle [Hu *et al*., 2014b]. This decides the direction and morphology

of the electrospun item since it influences the properties of the electric field during electrospinning [Bhardwaj and Kundu, 2010; Pham *et al*., 2006].

3.1.3 Ambient parameters

- **Temperature**

The environmental temperature influences the dissolvable dissipation rate and consistency of polymer solution or softening [Su *et al*., 2011]. The impact of temperature on the arrangement or dissolve thickness is inverse for example higher temperatures bring about lower thickness and the development of more slender nanofibers.

- **Relative humidity**

The impact of relative humidity (RH) on electrospinning relies upon the creation of polymer solution. Because of hydrophobic polymers broken up in natural solvents, water goes about as a non-dissolvable and higher RH values lead to the development of permeable nanofibers [Medeiros *et al*., 2008a]. Because of dissolvable dissipation, a slim film of dried polymer is shaped on the stream surface and pores happen to permit the dissemination of ensnared dissolvable particles and complete nanofiber hardening [Medeiros *et al*., 2008b]. Because of watery polymer arrangements, RH can be utilized to control nanofiber width and their mechanical properties [Pelipenko *et al*., 2013b]. The changes in nanofiber morphology because of changes in RH can be clarified by the mix of two impacts, the dissolvable vanishing rate (hardening speed) and development of globule on-a-string morphology. At low RH values, fast dissolvable dissipation makes the polymer solution set before long it emerges from the nozzle, and it is exposed to voltage initiated extending for a more limited time frame period, which brings about thicker nanofibers. The hardening system is decelerated and the fluid in the electrospun jet has more opportunity to stream and be extended under the applied electric field when RH is higher. This is reflected first and foremost in the arrangement of more slender nanofibers, then, at that point in the continuous event of dab on-a-string electrospun item morphology, lastly in the development of a polymer film as an outcome of wet electrospun item statement and its combination on the gatherer [Pelipenko *et al*., 2013b].

The described factors and their impacts on nanofiber diameters created from fluid polymer solution are summed up in Table 1.

Table 1 - Effect of electrospinning parameters on nanofiber diameters produced from aqueous polymer solutions [adapted from J. Pelipenko *et al*., 2015a]

Increase in:	Nanofiber diameter
Polymer concentration	↑
Polymer molecular weight	↑
Surface tension	–
Bulk viscosity	↑
Conductivity	↓
Dielectric constant	↓
Applied voltage	↓
Nozzle tip-to-collector distance	–
Flow rate	↑
Nozzle inner diameter	↑
Temperature	↑ or ↓
Relative humidity	↓

4. Drug release and loading capacity

Active pharmaceutical ingredients can be joined within the nanofiber network, adsorbed, or artificially bounded to the nanofiber surface. [Bertoncelj *et al*., 2014] A numerous of possibilities can conveyed through nanofibers, including drugs (antibiotics, anticancer medications), proteins, peptides, compounds, cells, Deoxyribonucleic Acid/ Ribonucleic Acid [Sill, *et al*., 2008; Kai *et al*., 2016].

The most widely recognized technique for drug loading inside the nanofiber matrix is simple to perform a medication blend with a polymer before electrospinning [Beachley and Wen, 2010; Williams *et al*., 2012].

The distinctions in drug incorporation designs are identified by drug solvency and the amount stacked. The negligible part of the medication that can be joined to the nanofiber matrix relies upon its solvency in polymer scattering, drug–polymer collaborations, and the capacity of the medication to be adequate, as individual molecules, and stay unaltered during and after hardening [Mickova *et al*., 2012; Pinho *et al*., 2009].

The second drug loading strategy addresses the actual drug adsorption on the outside of the nanofibers. It works by dunking the nanofibers into a drug solution, which can connect with the surface through, for example, electrostatic cooperation. Notwithstanding, this strategy is only occasionally utilized because of its power over the drug discharge profile, and an unfortunate cutthroat medication dislodging with the segments of organic liquids. A choice

to tranquilize adsorption is to cover nanofibers with a coaxial spout, where the drug is stacked in the shell [Pelipenko *et al.*, 2015].

The third drug loading technique is the immobilization of the drug atoms on the outside of the nanofibers by covalent holding [Patel *et al.*, 2007]. This is predominately used to change nanofiber surface properties, since the interaction is actually perplexing. The covalent bound in the drug is delivered from the nanofibers, after the enzymatic or hydrolytic corruption of the compound connection between the drug and the polymer happens. The surface-formed nanofibers can be used as tissue frameworks or medication conveyance frameworks [Jang *et al.*, 2009]. To accomplish such appropriateness, a wide range of atoms can be effortlessly joined during the electrospinning interaction to deliver functionalized nanofibers.

A plan of different nanofiber drug loading is illustrated in Figure 4.



Figure 4 - Different methods of drug loading nanofibers. The active ingredient con be (1) - dissolved; (2) - suspended in unifform matrix; (3) - loaded in core and shell or (4) - attached to the nanofiber surface. [Adapted from Pelipenko et al., 2015]

Nanofibers as medication conveyance frameworks have numerous benefits because of the variety of polymers used [Pelipenko *et al.*, 2015]. To foster nanofibers with the ideal controlled medication discharge profile, the comprehension of the delivery instruments and the physicochemical cycles that influence the drug discharge are indispensable (Figure 5).



Figure 5 - Relationship between structural parameters of nanofibers and their drug release profile [Adapted from Kamble et al., 2017]

Lipophilic drugs are stacked in lipophilic polymers, while hydrophilic drugs are stacked in hydrophilic polymer arrangements. Medication delivery can be changed using a mix of hydrophilic hydrophobic polymers [Meng *et al.*, 2011; Jannesari *et al.*, 2011]. In any case, the deferred discharge profile can be custom-made by drug fuse into other nanocarriers, for example nanoparticles, liposomes, dendrimers; followed by their stacking into nanofibers [Hu *et al.*, 2014] or by utilizing hydrophobic polymers [Xie and Wang, 2006]. A normal delivery profile of such nanofibers shows an underlying burst discharge followed by a practically straight, supported delivery. Due to centre shell nanofibers, the centre can address a medication repository and the shell an obstruction, which ensures the consolidated medication and controls its delivery rate [Yu *et al.*, 2013b]. The burst discharge impact from such nanofibers is practically immaterial, and the whole delivery profile is supported [Rošic *et al.*, 2013]. Moreover, the different layers of such centre shell nanofibers can guarantee diverse medication discharge energy, bringing about drug conveyance frameworks with complex delivery profiles. Polymers with extremely high glasslike places are referred to as having more slow delivery rates, when contrasted with undefined districts because of low water take-up in exceptionally requested three-dimensional gem varieties [Chou *et al.*, 2015].

Drug related boundaries influencing its delivery structure nanofibers are drug stacking and of atomic weight - the actual condition of medication, solvency, and drug-polymer associations [Hrib *et al.*, 2015]. Generally, higher medication stacking is related to quicker delivery. The glasslike type of the medication gets saved on the nanofiber surface and gives burst discharge; while the shapeless structure gets stored further inside and gets delivered in

a supported way. Low sub-atomic weight drugs are known for their quick delivery rate [Natu *et al.*, 2010]. The development of an indistinct medication is supported because of the extremely restricted time accessible for drug crystallization, during the electrospinning cycle. An inventive methodology dependent on the joining of the drug to a nanocarrier (e.g., liposomes, strong lipid nanoparticles, micelles), trailed by consolidating into nanofibers has been growing [Mickova *et al.*, 2012; Pinho *et al.*, 2009]. There is yet an unmistakable absence of information about potential medication changes during electrospinning, and the capacity of electrospun items. This information addresses indispensable data for the plan of nanofibers as potential medication conveyance transporters [Sebe *et al.*, 2013].

Figure 6 shows drug related boundaries influencing drug release [Thakkar *et al.*, 2017]. Another use of bio conjugating drug particles with nanofiber surfaces can be found for a class of mixtures that corrupt and lose their usefulness like compounds, DNA or development factors [Mohammadian *et al.*, 2016].



Figure 6 - Effects of nanofiber diameter, porosity, alignment, polymer crystallinity and molecular weight on drug release [Adapted from Thakkar et al., 2017]

Upgrade responsive frameworks are reliant upon the rate by which improvements get moved to the comparing responsive material. Regarding nanofibers, their high proportion between surface region and volume makes them the adequate possibility for quicker reaction when contrasted with different materials [Frenot and Chronakis, 2003; Zhang and Yu, 2014].

Different electrospun nanofibers are accounted for upgrade responsive conveyance, upon openness to outer upgrades as pH, temperature, light, and others. Most of the specialists

have neglected to report medication components discharge, which could be a significant boundary; administering the general exhibition of improvements in responsive polymeric nanofibers [Demirci *et al*., 2014]. Considering the previously considerations, it can be presumed that nanofibers can be adequately utilized as a great possibility for boosting responsive medication conveyance [Thakkar *et al*., 2017].

5. Therapeutic applications

In the biomedical field, it's established that all tissues and organs such as skin, collagen, dentin, ligament, and bone, somehow, have a type of likeness to exceptionally coordinated, various levelled, nanosized sinewy constructions. Hence, research on biomedical applications has zeroed in on cancer therapy, scaffolds for tissue engineering, wound dressing, dementia/diabetes/ acquired immunodeficiency syndrome (AIDS) [Metreveli *et al*., 2014].

5.1 Cancer therapy

Cancer is known to be a disease described by the uncontrolled development of cells, which are fit for getting away from general body annihilation systems. Reports have shown an expansion in new cases, alongside patient death paces experiencing malignant growth; showing genuine deficiency of the current treatment methodologies [Thakkar *et al*., 2017]. In any case, the utilization of electrospinning fiber mats for chemotherapy became recently popular. Contrasted and other dose structures like liposomes, micelles, hydrogels, and nanoparticles, electrospun mats can decrease the framework harmfulness and increment the nearby medication fixation. Particularly on account of strong tumours, a mix of careful activity for eliminating the tumour with chemotherapy or radiation treatment is the typical system to lessen the likelihood of recurrence [S. Liu *et al*., 2013].

Different anticancer drugs like doxorubicin (Dox), paclitaxel (PTX), platinum complexes [Xie *et al*., 2008], and dichloroacetate have been electrospun into filaments and utilized for postoperative nearby chemotherapy. For instance, *Xu et al.* revealed planning of ultrafine Dox-containing poly(ethylene glycol)-poly(L-lactic acid) (PEG-PLLA) strands by electrospinning a water-in-oil emulsion, in which the watery stage contained water-solvent medications, and the sleek stage was a chloroform arrangement of PEG–PLLA. The outcomes showed that the Dox was completely embodied inside the electrospun filaments [Xu *et al*., 2008]. Thereafter, they effectively stacked hydrophobic PTX and hydrophilic Dox into PEG–PLLA nanofiber mats, by the emulsion-electrospinning strategy and acknowledged multi-drug conveyance [X. Xu *et al*., 2009]. *Xie et al.* manufactured cisplatin-stacked PLA/PLGA (30/70) strands for long haul supported conveyance of cisplatin to treat C6 glioma *in vitro* [Xie *et al*.,

2008]. The medication embodiment proficiency was over 90% and the cisplatin-stacked strands showed supported delivery for over 75 days without introductory burst discharge.

Local chemotherapy is a decent decision for the therapy of an unresectable cancer or for the avoidance of a post-medical procedure tumour repetition. *Liu et al.* arranged Dox epitomized nanofibers, utilizing poly(L-lactic acid) (PLLA) as the transporter, and analysed it's anything but a neighbourhood chemotherapy framework against Singular Hepatocellular Carcinoma (SHCC) [Liu *et al.*, 2013]. The outcomes showed that most of the stacked Dox in the strands was delivered and diffused into the tumours' site under the fiber mat, prompting an incredible inhibitory impact on the tumour's development and little harm to different organs. These outcomes give an empowering prospect for utilizing drug-stacked electrospun nanofibers in neighbourhood chemotherapy, particularly for those patients getting total tumour resection or a cytoreductive medical procedure. Likewise, *Ranganath et al.* arranged PTXl-stacked nanofibers and assessed their post-careful chemotherapy impact against dangerous glioma [Ranganath *et al.*, 2008]. *Liu et al.* joined dichloroacetate (DCA) with PLA non-woven textures by electrospinning. These DCA-stacked electrospun mats were straightforwardly embedded to cover the strong tumours [Liu *et al.*, 2012]. Results demonstrated that a tumour concealment level of 96% was accomplished in under 19 days. The strong subcutaneous tumours totally vanished from half of the tumour-bearing mice. *Luo* arranged hydroxycamptothecin stacked poly(benzaldehyde-poly (ethylene glycol))- poly(D,L-lactide) (PBELA) strands for intratumorally implantation and unrivalled antitumour action; and less incidental effects were noticed [Luo *et al.*, 2013].

5.2 Scaffolds for tissue engineering

Nanofibers can influence the morphology and mechanical properties of cells, which can prompt modifications in cell correspondence, further prompting changed tissue usefulness. Cell reactions on nanofibrillar support are different and cell-line explicit; for instance, keratinocytes refined on haphazardly situated nanofibers receive an adjusted morphology and apply lower solidness because of changes in cytoskeleton association [Pelipenko *et al.*, 2013a]. Then again, the morphological changes of fibroblasts are less critical. At the point when cells are developed on adjusted nanofibers, they receive a lengthened morphology, joined by a serious level of cytoskeleton association and more prominent firmness [Jankovic *et al.*, 2013]. Numerous tissues in the body like nerves, vascular tissue, or skeletal tissue show a serious level of cell request, which guarantees the tissue's usefulness. Arranged cell development can be accomplished using adjusted nanofibers, as was displayed in various investigations [Alves *et al.*, 2010; Huang *et al.*, 2012; Zhang *et al.*, 2011]. It is all around recorded that cell receive equal

direction on adjusted substrates; and when refined on rectangularly-situated nanofibers, the cell development is directed at the edges of the nanofibers stored in a rectangular example [Pelipenko *et al*., 2013a]. Besides, the cells take after the state of nanofibers, with an unmistakably prolonged morphology. The length of keratinocytes developed on a level glass surface is around 30mm, yet on account of adjusted nanofibers the cells arrive at 80mm or longer. A comparative impact was seen on account of fibroblasts. It was, likewise, archived that when a cell is in touch with an adjusted nanofiber, filopodia specially stick to the nanofiber and totally withdraw from the level surface [Albuschies and Vogel, 2013].

Nanofibers are frequently referenced as a promising material for the incitement of three-dimensional tissue recovery, but they have not been viable up until now. Due to nanosized interfibrillar pores, nanofibers impair effective ingrowth of cells into more profound layers of nanofibrillar support and are, consequently, reasonable just for two-dimensional tissue regeneration [Pelipenko *et al*., 2013a].

Powerful cell attachment on a tissue substitute is certainly the initial phase in effective tissue recovery, and ought to be trailed by quick cell movement from the edges towards the focal point of the framework, which would bring about quicker twisted conclusions. It is influenced by the material's hydrophilicity/hydrophobicity, nano topography, mechanical properties, and useful gatherings on nanofiber surface [Pelipenko *et al*., 2013a; Pelipenko *et al*., 2015; Yang *et al*., 2011]. Reports on the impacts of nanofibrillar geography on the pace of cell grip are conflicting. Some have shown acceleration [Bhattarai *et al*., 2004] and others a decelerated bond [Pelipenko *et al*., 2013a]. This could be the outcome of various materials (hydrophobic on one side and hydrophilic on the other) utilized for nanofiber arrangement, prompting diverse nanofiber expanding conduct [Jankovic *et al*., 2013]. In any case, it has effectively been shown that cell grip can be constrained by the surface change of nanofibers [Jeong *et al*., 2010], or by modifications in nanofiber measurement [Tian *et al*., 2008]. It has likewise been seen that the strength of cell bond is expanded when cells are cultivated on a nanofibrillar support [Pelipenko *et al*., 2013a]. The explanation lies in the way nanofibers manage the articulation of integrins responsible for cell binding. Another clarification could be the actual entanglement of cells in the nanofibrillar support because the cell's adaptable pieces enter the more profound layers of the nanofibrillar support [Pelipenko *et al*., 2013a].

The point of tissue designing is to deliver a framework that can briefly supplant the harmed Extracellular Matrix (ECM) and quickly offer help for cell development, and consequently speed up tissue recovery. Biodegradable tissue substitutes are intended to offer

time-restricted help; in this way, it is significant that they invigorate the union of the normal ECM. A few investigations have shown that nanofibrillar designs can incite endogenous ECM creation, and that stored ECM can be better coordinated [Lee *et al.*, 2005]. *Li et al.* demonstrated that chondrocytes, when refined on PCL nanofibers, produce a more sulphated proteoglycan-rich cartilaginous lattice than those refined on a level surface [Li *et al.*, 2003], and creation of glycosaminoglycan is higher on a nanofibrillar mesh than on a micro level [Li *et al.*, 2006].

5.3 Wound dressing

Materials used in wound dressing materials are intended for establishing and keeping a climate, which is generally appropriate for twisted mending by giving simple vaporous trade, retaining exudates from the injury site, and giving a sterile climate, which doesn't uphold microbial development. Utilization of anti-infection stacked nanofibers as wound dressing material serves a few benefits because of porosity, high surface region to volume proportion and biocompatibility [Li *et al.*, 2017].

Ignatova et al. summed up different anti-toxins like antibiotic medication hydrochloride, ciprofloxacin, levofloxacin and moxifloxacin; and antibacterial specialists (e.g., 8-hydroxyquinoline subsidiaries, itraconazole, benzalkonium chloride (BC), fusidic acid or silver nanoparticles) embodied in nanofibers forwound-dressing [M. Ignatova *et al.*, 2013]. In deepest cases, PLA, PLGA and PCL were utilized as transporter polymers, and other manufactured or normal polymers were added to direct the biodegradability and hydrophilic's nature of the filaments, in this manner controlling the release behaviour. For instance, in the early investigation on the use of electrospun nano-filaments for drug conveyance by *Kenawy et al.* [Kenawy *et al.*, 2002], hydrochloride antibiotic medication was utilized as a model medication, and poly(ethylene-co-vinyl acetic acid derivation), PLA and their mixes were utilized as polymeric transporters. The outcomes exhibited that the medication discharge conduct was affected by the idea of polymeric transporters and medication content. Smooth and a managed drug discharge, over roughly 5 days, was gotten by electrospinning 50/50 mix with somewhat low medication content (5%). Higher medication content (25%) initiated a substantially quicker delivery than the 5% test because of the more surface-isolation of the medication in the previous case.

The fuse of metals into electrospun fiber mats has, likewise, been utilized to kill organisms, target bacterial colonization, and restrain tainting. *Thomas et al.* consolidated biosynthesized Silver Nanoparticles (AgNPs) into PCL nanofibers by means of electrospinning

and exhibited antimicrobial impacts against *Staphylococcus epidermidis* and *Staphylococcus haemolyticus* [Thomas *et al.*, 2015]. Similarly, *Dashdorj et al.* fused AgNPs into zein (a corn protein) nanofibers and showed bactericidal action against *Staphylococcus aureus* and *Escherichia coli* [U. Dashdorj *et al.*, 2015]. *Ghavami Nejad et al.* utilized electrospinning to frame AgNPs on the outside of poly(dopamine methacrylamide-co-methyl methacrylate) (MADO) strands [Ghavami Nejad *et al.*, 2015]. The strands delivered ~13% of the Ag payload within 1 day, trailed by a slower delivery for the following 6 days. Furthermore, the fiber mats had bactericidal movement against *Staphylococcus aureus, Escherichia coli*, and *Pseudomonas aeruginosa*. An *in vivo* rodent study affirmed the viability of AgNPs-MADO fiber mats, where full thickness wounds treated for 15 days showed higher injury mending rates (92%), contrasted with controls (51%) and MADO-alone fiber mats (65%). Essentially, *Woo et al.* fostered a bilayered build with an upper layer consisting of TiO_2-stacked chitosan nanofibers, and a lower layer consisting of human fat determined extracellular network [Woo *et al.,* 2015]. The bilayered development was displayed to have an *in vitro* bactericidal movement against *Staphylococcus aureus* and *Escherichia coli* and hinder bacterial infiltration and speed up injury mending *in vivo* in a rodent model.

The therapy of cutaneous injuries like consumes awful cutaneous wounds and ongoing injuries is right now a critical clinical test. Normally, ordinary cutaneous injury mending is arranged into three time-subordinate stages: (I) aggravation, begins following injury; (ii) new tissue development, covers with the main stage; and (iii) tissue reorganization, where scar tissue is shaped and may rebuild for a year or more [L. Macri *et al.*, 2009]. Commonly, injury recuperating is unreasonable, as there is no cell wellspring staying for recovery. In persistent injuries, the irritation stage regularly continues unreasonably long, bringing about injuries that stay open for quite a long time, even years. In these kinds of wounds, dressings assume a significant part to (I) secure the injury; (ii) keep a sodden injury climate; (iii) shield the injury from defilement with exogenous microorganisms; and (iv) speed up injury conclusion. For instance, *Wang et al.* covered electrospun centre shell filaments made of PCL/hyaluronic acid, containing the epidermal development factor (EGF). This plan sped up injury conclusion *in vivo* [Wang *et al*, 2015]. A few different gatherings have additionally covered the impregnation of EGF [Norouzi *et al.*, 2015], the basic fibroblast development factor (bFGF) [Y. Yang et al, 2011], the vascular endothelial development factor (VEGF), and the platelet-inferred development factor-BB (PDGF-BB) [Lai *et al*., 2014] into electrospun fiber mats, as a methodology for speeding up injury conclusion. Foundational and effective organization of ketanserin, a specific S2-serotonin, sped up injury mending of diabetic foot ulcers [Quatresooz

et al., 2006]. *Macri et al.* consolidated a fibronectin-determined peptide that holds guarantee in the treatment of burns [Zhu *et al.*, 2014] into tyrosine inferred polycarbonates, utilizing a standard electrospinning arrangement. It was shown that both polymer structure and medication stacking altogether influenced *in vitro* drug discharge [Macr *et al.*, 2012]. As of late, *Peh et al.* impregnated a mixed drink (Vitamin C, hydrocortisone, insulin, triiodothyronine, EGF, and Vitamin D3) in electrospun PLGA/collagen fiber mats and tried their likely utility in injury recuperating applications. These scientists additionally affirmed the bioactivity of the delivered atoms *in vitro* [Peh *et al.*, 2015].

5.4 Dementia

Dementia related with Alzheimer's disease is a significant neurodegenerative illness in old patients. Different medications utilized for treatment are donepezil, rivastigmine, galantamine and others. *Gencturk et al.* has revealed the polyurethane/HPC nanofiber arrangement of donepezil hydrochloride medication for a well-prepared administration of Alzheimer's disease-related dementia (Figure 7). The transdermal polymeric mat of the medication showed powerful dispersion-controlled conveyance of medication, following a Korsmeyer–Peppas discharge energy. *In vitro* MTT cytotoxicity concentrates examine the nanofiber mat to be fully hardened and not aggravate the skin [Gencturk *et al.*, 2017]. The result reported by Aricept for the medicine donepezil hydrochloride is available as oral decomposition tablets containing 5 and 10 mg of the medicine. Joining the medication with the nanofiber mat could give simple command over portion too, as it can bring about better persistent consistency in dementia.

Horrible or potentially careful mind injury is related with different neurotic changes, leading to extreme parenchymal harm in the cerebrum. *Sulejczak et al.* has revealed deferred/lessens neuro-damaging marvels after dressing with a L-lactide-caprolactone copolymer nanofiber net, while the stripped rodent model of careful cerebrum injury was having enormous neurodegeneration and scar development (Figure 7) [Sulejczak *et al.*, 2014]. Exploratory outcomes demonstrated the capacity of biodegradable polymer-based nanofiber mats in lessening scar arrangement, related with different cerebrum wounds, which in any case could hamper the appropriate working of the mind. *Xie et al.* have detailed a plan of PTX-stacked PLGA nanofibers for the treatment of cerebrum tumours, as an elective medication conveyance gadget. The epitome proficiency of the medication in nanofibers was discovered to be over 90%. Differential Scanning Calorimetry (DSC) investigation was done in the examination to see the strong state property of the medication, and it was discovered to be available in a strong arrangement state. Supported arrival of PTX was accounted for alongside

IC50 esteem, which was equivalent to the business item in the cytotoxicity exam (Figure 7) [Sulejczak *et al.*, 2014]. The main restriction of the study mentioned above is the need for a primer medical procedure to locate a biodegradable and embedded drug, having a dangerous development. Legitimate examinations referencing any conceivable unloading portion ought to be led when working with anticancer drug loaded nanofibers, which would somehow be related with serious poison levels. In the greater part of the examinations announced till date, issues identified with the homogeneity of the medication are not attended to. This turns out to be considerably more relevant, if drug viable is incredibly intense (like anticancer medications) and not totally dissolvable in the pre-arranged polymer arrangement, bringing about non-homogenous conveyance. Restorative specialists showing an impact at low fixation should be appropriately analysed for their homogeneity in the example, especially when the medication is to be fused in a suspended structure or glasslike structure. It is suitable, under such conditions, to gather uniformly sized tests (of nanofiber sheets fused with medicine) from several pieces of the collecting plate and break the measure of the medicine to avoid any problems related to the medicine's consistency. But most investigations did not reveal the drug type (glasslike or undefined) as well as % stacking, which could be a significant boundary for the drug-discharge properties of nanofibers, as described in the previous areas. The type of drug leads to reflection on the discharge profile, as well as it is crucial to discover the location where a plausible drug claim will take place (by all reports or deeper within the nanofiber), making it a significant threshold for the researcher in improving a plan [Thakkar *et al.*, 2017].



Figure 7 - Examples of nanofibers mediated drug therapy [Adapted from Thakkar et al., 2017]

5.5 Cardiovascular and vascular disorders

At the point when the heart gets lower volumes of oxygenated blood, it brings about Angina pectoris. Potassium channel openers are the class of mixtures that are currently habitually utilized for hypertension states just as angina pectoris. *Singh et al.* have detailed readiness of a nanofiber plan of such class of mixtures and have shown its utilization for the treatment of conditions like angina. Nicorandil as a medication applicant is related with issues of low bioavailability, moderate beginning of activity and mucosal ulceration at the site of activity. A few transporter frameworks have been attempted with medication and have shown no improvement of the mucosal ulceration difficulties and postponed the beginning of activity. Creators and associates have revealed planning of polymeric nanofibers of the nutrient B-12 and a mix of hyaluronic acid, and PVA stacked with nicorandil drug, for its sublingual conveyance. Electrospun nanofibers were discovered to be uniform, non-beaded with breadths of 200–450 nm. *In-vitro* drug discharge has shown supported medication discharge throughout an extensive period of time. Histopathological pictures uncovered the shortfall of mucosal ulceration at the site of use [Thakkar *et al.*, 2017].

This investigation shows the capability of nicorandil nanofibers in defeating obstacles identified with its conveyance [Singh *et al.*, 2016]. These sorts of approaches could be successfully used to convey drugs having solvency issues and require moment impact; for example, in the administration of agony. Additionally, restorative actives having exceptionally high first pass digestion can be planned as oral patches having nanofibers comprising of prompt delivery polymers. Intracranial aneurism is another illness identified with a cerebrovascular framework, which eventually can prompt haemorrhagic stroke, cerebrum harm and demise. *Wang et al.* have revealed detailing of PLLA-PCL nanofibers stacked with an intense anticoagulant, heparin, and vascular endothelial development factor. Filaments were accounted for when covered on the stent surface, for use in the treatment of intracranial aneurism. Delivery profiles have shown the dependable arrival of both the moieties for over 30 days with no underlying burst discharge impact. This investigation has shown the capability of medication nanofiber covered stent for the treatment of an aneurism, and enlistment of endothelialisation [Wang *et al.*, 2016]. For some reasons, the vascular medical procedure is related with prosthetic unite diseases. Medication conveyance framework, which can transmit anti-infection agents locally in a supported delivery example, can provide a successful method of treatment for these sorts of contaminations. *Liu et al.* have revealed arrangement of a biodegradable nanofiber stacked vascular prosthetic unit for supported delivery and neighbourhood conveyance of vancomycin in the treatment of vascular diseases. Eluting

technique has shown the higher arrival of medication for over 30 days. At last, *in-vivo* implantation of nanofiber stacked unions in subcutaneous pockets of bunnies has shown the capability of these frameworks for viable prosthetic join diseases [Liu *et al*., 2015].

5.6 Diabetes

Diabetes is one of the major and perilous illnesses of the 21st century. A few microvascular and macrovascular difficulties are related with diabetes, such as impact on retina, kidneys, and dangers of heart sicknesses. These complexities can, for the most part, be limited with the control of the blood glucose level. Electrospinning procedure has been used in the development of biosensors, just as in the treatment of infections. *Vellayappan et al.* have shown a viable examination of customary biosensors with cutting edge electrospun biosensors, which give understanding into the utilization of electrospinning for the arrangement of biosensors [Vellayappan *et al*., 2016]. Injectables can give successful conveyance of insulin against diabetic medications, yet it is related with the helpless patient consistency. To foster an oral method for the diabetes treatment is quite difficult for drug researchers till date. *Xu et al.* have revealed arrangement of gelatin/insulin strands by co-electrospinning, for transbuccal conveyance of insulin. Expanded arrival of insulin was found for 4 h. Delivered insulin was checked for showing action and was found to effectively trigger intracellular AKT phosphorylation. Results finished up fruitful with transbuccal conveyance of insulin from gelatin/insulin strands defined by co-electrospinning of gelatin and insulin [Xu *et al*., 2015]. Another electrospinning-based nanofiber plan for diabetic hostile impact was accounted by *Modgill et al*. in 2015. They have shown the development of linagliptin stacked PVA nanofibers to frame a biodegradable polymeric sheet. Arranged nanofibers were accounted for to have an exemplification productivity of 92%. When assessed for mucoadhesive strength, drug-stacked nanofiber patches were found to have higher mucoadhesion, when contrasted with clear nanofibers. Most likely because of a higher surface region and water holding limit. Results were discovered to be practically identical with the endless supply of *in-vivo* action [Modgill *et al*., 2015]. *Choi et al.* have announced nanofibers with bFGF and EGF for the treatment of diabetic ulcers; it detailed an increment in amassing of both collagen and solidified grid of keratin. These discoveries show promising potential nanofibers mats in the treatment of diabetic ulcers [Choi *et al*., 2011].

5.7 Acquired Immunodeficiency Syndrome

AIDS is a condition caused by human immunodeficiency infection (HIV), which unfavourably influences the invulnerability of the patient, making him/her more powerless against different diseases. It usually requires a blend or multidrug treatment with antiretroviral

specialists. *Blakney et al.* have revealed planning of stacked PVA nanofibers for the consolidated treatment with tenofovir and levonorgestrel medication, for the anticipation of HIV procurement. Results show the conservation of the antiviral movement of tenofovir medication, after discharge from nanofibers with no harmful impacts. The presence of levonorgestrel showed not to influence the delivery and pharmacodynamic profile of tenofovir (Blakney *et al*., 2014). *Ball et al.* have revealed planning of nanofibers of PEO/PLLA mixes, stacked either with maraviroc or acyclovir, for the movement against HIV contamination. Medication discharge profile for both medications was discovered to be shifted dependent on the proportion of polyethylene oxide (PEO)/PLLA mixes. Successful HIV hindrance was accounted for drug-stacked strands upon *in-vitro* assessment (Ball *et al*., 2012). Zovirex™ is the promoted result of acyclovir utilized for oral organization; these acyclovir-stacked nanofibers can give a simple other option if bioavailability profiles are comparable. Examination of the pre-arranged plan with advertised item, in terms of delivery, might have accommodated simple correlation.

6. Final remarks and future perspectives

Although nanofibers have shown incredible potential for drug conveyance applications; there are difficulties which should be dodged before nanofibers can be utilized as medication conveyance vehicles. Till date certain central points, including drug loading, the security of dynamic fixings, starting burst discharge, the measure of leftover solvents and modern scale-up are essential bottlenecks, which should be defeated prior to bringing this innovation into standard medication conveyance advancements. Polymers (either engineered or natural) which are a typical fixing to give the spine to the nanofibers and are accounted for to cause amorphization of glasslike drug applicants. The presence of a functioning fixing in reasonable structure whether nebulous or translucent will significantly affect dependability, particularly on account of medications, where administrative standards are extremely tough and necessitate that polymorphic type of the medication be determined at all essential stages, including steadiness. Aside from this, drug stacking in polymer arrangement may antagonistically influence its consistency and surface pressure delivering it inadmissible for electrospinning [Yu *et al*., 2009].

Scale-up of nanofiber creation by electrospinning is again problematic. Research center scale machines are for the most part managing little volumes in milliliters and with regards to liters in mechanical scale the thing presents bunches of difficulties and there is space for additional improvement of interaction and hardware [Persano *et al*., 2013].

Henceforth it is beneficial that this load of difficulties should be surely known and controlled before nanofibers acquired utilizing electrospinning could be utilized in standard medication conveyance advances offering wanted medication discharge profile and satisfactory drug loading [Thakkar *et al*., 2017].

Bibliography

Albuschies J and Vogel V (2013). **The role of filopodia in the recognition of nanotopographies**. Sci Rep; 3:1658. doi:10.1038/srep01658.

Alves NM, Pashkuleva I, Reis RL, Mano JF (2010). **Controlling cell behavior through the design of polymer surfaces**. Small; 6(20):2208-20. doi: 10.1002/smll.201000233.

Angammana CJ and Jayaram SH (2011). **Analysis of the effects of solution conductivity on electrospinning process and fiber morphology**. Industry Applications, IEEE Transactions on Industry Applications; 47(3):1109–1117.

Ball C, Krogstad E, Chaowanachan T, Woodrow KA (2012). **Drug-eluting fibers for HIV-1 inhibition and contraception.** PLoS One; 7(11):e49792. doi: 10.1371/journal.pone.0049792.

Beachley V and Wen X (2010). **Polymer nanofibrous structures: Fabrication, biofunctionalization, and cell interactions**. Prog Polym Sci; 35(7):868-892. doi: 10.1016/j.progpolymsci.2010.03.003.

Bertoncelj V, Pelipenko J, Kristl J, Jeras M, Cukjati M, Kocbek P (2014). **Development and bioevaluation of nanofibers with blood-derived growth factors for dermal wound healing**. Eur J Pharm Biopharm; 88(1):64-74. doi: 10.1016/j.ejpb.2014.06.001.

Bhardwaj N and Kundu SC (2010). **Electrospinning: a fascinating fiber fabrication technique.** Biotechnol Adv; 28(3):325-47. doi: 10.1016/j.biotechadv.2010.01.004.

Bhattarai SR, Bhattarai N, Yi HK, Hwang PH, Cha DI, Kim HY (2004). **Novel biodegradable electrospun membrane: scaffold for tissue engineering.** Biomaterials; 25(13):2595-602. doi: 10.1016/j.biomaterials.2003.09.043.

Blakney AK, Krogstad EA, Jiang YH, Woodrow KA (2014). **Delivery of multipurpose prevention drug combinations from electrospun nanofibers using composite microarchitectures.** Int J Nanomedicine; 9:2967-78. doi: 10.2147/IJN.S61664.

Cai L, Heilshorn SC (2014). **Designing ECM-mimetic materials using protein engineering.** Acta Biomater; 10(4):1751-60. doi: 10.1016/j.actbio.2013.12.028.

Choi JS, Choi SH, Yoo HS (2011). **Coaxial electrospun nanofibers for treatment of diabetic ulcers with binary release of multiple growth factors**. J Mater Chem; 21:5258-5267.

Chou SF, Carson D, Woodrow KA (2015). **Current strategies for sustaining drug release from electrospun nanofibers**. J Control Release; 220 (Pt B): 584-91. doi: 10.1016/j.jconrel.2015.09.008.

Cramariuc B, Cramariuc R, Scarlet R, Manea LR, Lupu IG, Cramariuc O (2013). **Fiber diameter in electrospinning process**. J. Electrostat. 71, 189–198.

Dashdorj U, Reyes MK, Unnithan AR, Tiwari AP, Tumurbaatar B, Park CH, Kim CS (2015) **Fabrication and characterization of electrospun zein/Ag nanocomposite mats for wound dressing applications**, Int. J. Biol. Macromol. 801–7.

Demirci S, Celebioglu A, Aytacab Z, Uyar T (2014). **pH-responsive nanofibers with controlled drug release properties**. Polym. Chem. 5:2050–2056.

Frenot A and Chronakis IS (2003). **Polymer nanofibers assembled by electrospinning**. Curr Opin Colloid In; 8:64–75.

Gencturk A, Kahraman E, Güngör S, Özhan G, Özsoy Y, Sarac AS (2017). **Polyurethane/hydroxypropyl cellulose electrospun nanofiber mats as potential transdermal drug delivery system: characterization studies and in vitro assays**. Artif Cells Nanomed Biotechnol; 45(3):655-664. doi: 10.3109/21691401.2016.1173047.

Geng X, Kwon OH, Jang J (2005). **Electrospinning of chitosan dissolved in concentrated acetic acid solution**. Biomaterials; 26(27):5427-32. doi: 10.1016/j.biomaterials.2005.01.066.

GhavamiNejad A, Rajan Unnithan A, Ramachandra Kurup Sasikala A, *et al*. (2015). **Mussel-Inspired Electrospun Nanofibers Functionalized with Size-Controlled Silver Nanoparticles for Wound Dressing Application**. ACS Appl Mater Interfaces; 7(22):12176-83. doi: 10.1021/acsami.5b02542.

Guimarães A, Martins A, Pinho ED, Faria S, Reis RL, Neves NM (2010). **Solving cell infiltration limitations of electrospun nanofiber meshes for tissue engineering applications**. Nanomedicine (Lond); 5(4):539-54. doi: 10.2217/nnm.10.31.

Gupta P, Elkins C, Long TE, Wilkes GL (2005). **Electrospinning of linear homopolymers of poly(methyl methacrylate): exploring relationships between fiber formation, viscosity, molecular weight and concentration in a good solvent**. Polymer; 46(13):4799–4810.

Haghi AK and Akbari M (2007). **Trends in electrospinning of natural nanofibers**. Phys. Status Solidi A; 204(6):1830–1834.

Haider A, Haider S, Kang I-K (2018). **A comprehensive review summarizing the effect of electrospinning parameters and potential applications of nanofibers in biomedical and biotechnology**. Arab J Chem; 11(8):1165–1188.

Hartgerink JD, Beniash E, Stupp SI (2001). **Self-assembly and mineralization of peptide-amphiphile nanofibers**. Science; 294(5547):1684-8. doi: 10.1126/science.1063187.

Hassan MA, Yeomb BY, Wilkie A, Pourdeyhimi B, Khan SA (2013). **Fabrication of nanofiber meltblown membranes and their filtration properties**. J Membr Sc; 427:336e344.

Hrib J, Sirc J, Hobzova R, *et al*. (2015). **Nanofibers for drug delivery - incorporation and release of model molecules, influence of molecular weight and polymer structure**. Beilstein J Nanotechnol; 6:1939-45. doi: 10.3762/bjnano.6.198.

Hu J, Zeng F, Wei J, Chen Y, Chen Y (2013). **Novel controlled drug delivery system for multiple drugs based on electrospun nanofibers containing nanomicelles**. J Biomater Sci Polym Ed; 25(3):257-68. doi: 10.1080/09205063.2013.852367.

Hu X, Liu S, Zhou G, Huang Y, Xie Z, Jing X (2014). **Electrospinning of polymeric nanofibers for drug delivery applications**. J Control Release; 185:12–21.

Huang C, Fu X, Liu J, Qi Y, Li S, Wang H (2012). **The involvement of integrin β1 signaling in the migration and myofibroblastic differentiation of skin fibroblasts on anisotropic collagen-containing nanofibers.** Biomaterials; 33(6):1791-800. doi: 10.1016/j.biomaterials.2011.11.025.

Huang L, Nagapudi K, Apkarian RP, Chaikof EL (2001). **Engineered collagen-PEO nanofibers and fabrics**. J Biomater Sci Polym Ed; 12(9):979-93. doi: 10.1163/156856201753252516.

Huang Y, Song J, Yang C, Long Y, Wu H (2019). **Scalable manufacturing and applications of nanofibers**. Mater Today; 28:98–113.

Ibrahim YS, Hussein EA, Zagho MM, Abdo GG, Elzatahry AA (2019). **Melt Electrospinning Designs for Nanofiber Fabrication for Different Applications**. Int J Mol Sci; 20(10):2455. doi:10.3390/ijms20102455.

Ignatova M, Rashkov I, Manolova N (2013). **Drug-loaded electrospun materials in wound-dressing applications and in local cancer treatment**. Expert Opin Drug Deliv; 10(4):469-83. doi: 10.1517/17425247.2013.758103..

Ito Y, Hasuda H, Kamitakahara M, *et al*. (2005). **A composite of hydroxyapatite with electrospun biodegradable nanofibers as a tissue engineering material**. J Biosci Bioeng; 100(1):43–9.

Jang JH, Castano O, Kim HW (2009). **Electrospun materials as potential platforms for bone tissue engineering**. Adv Drug Deliv Rev; 61(12):1065-83. doi: 10.1016/j.addr.2009.07.008.

Jankovic B, Pelipenko J, Skarabot M, Musevic I, Kristl J (2013). **The design trend in tissue-engineering scaffolds based on nanomechanical properties of individual electrospun nanofibers.** Int J Pharm; 455(1-2):338–347.

Jannesari M, Varshosaz J, Morshed M, Zamani M (2011). **Composite poly(vinyl alcohol)/poly(vinyl acetate) electrospun nanofibrous mats as a novel wound dressing matrix for controlled release of drugs**. Int J Nanomedicine; 6:993-1003. doi:10.2147/IJN.S17595.

Jarusuwannapoom T, Hongrojjanawiwat W, Jitjaicham S, *et al* (2005). **Effect of solvents on electro-spinnability of polystyrene solutions and morphological appearance of resulting electrospun polystyrene fibers**. Eur Polym J; 41(3):409–421.

Jeong SI, Krebs MD, Bonino CA, Khan SA, Alsberg E (2010). **Electrospun alginate nanofibers with controlled cell adhesion for tissue engineering.** Macromol Biosci; 10(8):934-43. doi: 10.1002/mabi.201000046.

Jiang H, Wang L, Zhu K (2014). **Coaxial electrospinning for encapsulation and controlled release of fragile water-soluble bioactive agents**. J Control Release; 193:296-303. doi: 10.1016/j.jconrel.2014.04.025.

Kai D, Ren W, Tian L, *et al.* (2016). **Engineering poly(lactide)-lignin nanofibers with antioxidant activity for biomedical application.** ACS Sustain Chem Eng; 4(10):5268–5276.

Kamble P, Sadarani B, Majumdar A, Bhullar S (2017). **Nanofiber based drug delivery systems for skin: A promising therapeutic approach**. Journal of Drug Delivery Science and Technology; 41:124-133.

Kenawy el-R, Bowlin GL, Mansfield K, *et al.* (2002). **Release of tetracycline hydrochloride from electrospun poly(ethylene-co-vinylacetate), poly(lactic acid), and a blend**. J Control Release; 81(1-2):57-64. doi: 10.1016/s0168-3659(02)00041-x.

Ki CS, Baek DH, Gang KD, Lee KH, Um IC, Park YH (2005). **Characterization of gelatin nanofiber prepared from gelatin–formic acid solution**. Polymer; 46(14):5094–5102.

Kim K, Luu YK, Chang C, *et al* (2004). **Incorporation and controlled release of a hydrophilic antibiotic using poly(lactide-co-glycolide)-based electrospun nanofibrous scaffolds**. J Control Release; 98(1):47-56. doi: 10.1016/j.jconrel.2004.04.009.

Kriegel C, Kit KM, McClements DJ, Weiss J (2009). **Electrospinning of chitosan– poly(ethylene oxide) blend nanofibers in the presence of micellar surfactant**. Polymer; 50(1):189–200.

Lai HJ, Kuan CH, Wu HC, *et al.* (2014). **Tailored design of electrospun composite nanofibers with staged release of multiple angiogenic growth factors for chronic wound healing**. Acta Biomater; 10(10):4156-66. doi: 10.1016/j.actbio.2014.05.001.

Lee CH, Shin HJ, Cho IH, *et al.* (2005). **Nanofiber alignment and direction of mechanical strain affect the ECM production of human ACL fibroblast**. Biomaterials; 26(11):1261-70. doi: 10.1016/j.biomaterials.2004.04.037.

Li H, Ke Y, Hu Y (2006). **Polymer nanofibers prepared by template melt extrusion**. J Appl Polym Sci; 99(3):1018–1023.

Li H, Williams GR, Wu J, *et al*. (2017). **Thermosensitive nanofibers loaded with ciprofloxacin as antibacterial wound dressing materials**. Int J Pharm; 517(1-2):135-147. doi: 10.1016/j.ijpharm.2016.12.008.

Li WJ, Danielson KG, Alexander PG, Tuan RS (2003). **Biological response of chondrocytes cultured in three-dimensional nanofibrous poly(epsilon-caprolactone) scaffolds**. J Biomed Mater Res A; 67(4):1105-14. doi: 10.1002/jbm.a.10101.

Liu D, Liu S, Jing X, Li X, Li W, Huang Y (2012). **Necrosis of cervical carcinoma by dichloroacetate released from electrospun polylactide mats**. Biomaterials; 33(17):4362-9. doi: 10.1016/j.biomaterials.2012.02.062.

Liu H, Ding X, Zhou G, Li P, Wei X, Fan Y (2013). **Electrospinning of nanofibers for tissue engineering applications**. J Nanomater; 11:3.

Liu KS, Lee CH, Wang YC, Liu SJ (2015). **Sustained release of vancomycin from novel biodegradable nanofiber-loaded vascular prosthetic grafts: in vitro and in vivo study**. Int J Nanomedicine; 10:885-891. doi:10.2147/IJN.S78675.

Liu S, Zhou G, Liu D, *et al*. (2013). **Inhibition of orthotopic secondary hepatic carcinoma in mice by doxorubicin-loaded electrospun polylactide nanofibers**. J Mater Chem B; 1;101–109.

Luo X, Xie C, Wang H, Liu C, Yan S, Li X. (2012) **Antitumor activities of emulsion electrospun fibers with core loading of hydroxycamptothecin via intratumoral implantation**. Int J Pharm. 2012 Apr 4;425(1-2):19-28. doi: 10.1016/j.ijpharm.2012.01.012. Epub 2012 Jan 14.

Ma PX and Zhang R (1999). **Synthetic nano-scale fibrous extracellular matrix**. J Biomed Mater Res; 46(1):60-72. doi: 10.1002/(sici)1097-4636(199907)46:1<60::aid-jbm7>3.0.co;2-h.

Macri L and Clark RA (2009). **Tissue engineering for cutaneous wounds: selecting the proper time and space for growth factors, cells and the extracellular matrix**. Skin Pharmacol Physiol; 22(2):83-93. doi: 10.1159/000178867.

Macri LK, Sheihet L, Singer AJ, Kohn J, Clark RA (2012). **Ultrafast and fast bioerodible electrospun fiber mats for topical delivery of a hydrophilic peptide**. J Control Release; 161(3):813-20. doi: 10.1016/j.jconrel.2012.04.035.

Maleki M, Latifi M, Amani-Tehran M, Mathur S (2013). **Electrospun core–shell nanofibers for drug encapsulation and sustained release**. Polym Eng Sci; 53 (8):1770–1779.

Martin CR (1996). **Membrane-based synthesis of nanomaterials**. Chem Mater; 8(8):1739–1746.

McKee MG, Wilkes GL, Colby RH, Long TE (2004). **Correlations of solution rheology with electrospun fiber formation of linear and branched polyesters**. Macromolecules; 37(5):1760–1767.

McKee MG, Layman JM, Cashion MP, Long TE (2006). **Phospholipid nonwoven electrospun membranes**. Science; 311(5759):353-5. doi: 10.1126/science.1119790.

Medeiros ES, Mattoso LHC, Ito EN, *et al*. (2008a). **Electrospun nanofibers of poly (vinyl alcohol) reinforced with cellulose nanofibrils**. J Biobased Mater Bioenergy; 2:231–242.

Medeiros ES, Mattoso LHC, Offeman RD, Wood DF, Orts WJ (2008b). **Effect of relative humidity on the morphology of electrospun polymer fibers.** Can J Chem; 86;590–599.

Megelski S, Stephens JS, Chase DB, Rabolt JF (2002). **Micro- and nanostructured surface morphology on electrospun polymer fibers**. Macromolecules; 35:8456–8466.

Meng Z, et al., (2011) **Preparation and characterization of electrospun PLGA/gelatin nanofibers as a potential drug delivery system**. Colloids Surfaces B Biointerfaces 84 (1) 97e102.

Metreveli G, Wagberg L, Emmoth E, Belak S, Strømme M, Mihranyan A (2014). **A size-exclusion nanocellulose filter paper for virus removal**. Adv Healthcare Mater; 3(10):1546–1550.

Mickova A, Buzgo M, Benada O, *et al*. (2012). **Core/shell nanofibers with embedded liposomes as a drug delivery system.** Biomacromolecules; 13(4):952-62. doi: 10.1021/bm2018118.

Modgill V, Garg T, Goyal AK, Rath G (2015). **Transmucosal delivery of linagliptin for the treatment of type- 2 diabetes mellitus by ultra-thin nanofibers**. Curr Drug Deliv; 12(3):323-32. doi: 10.2174/1567201811666141117144332.

Natu MV, Sousa HC, Gil MG (2010). **Effects of drug solubility, state and loading on controlled release in bicomponent electrospun fibers**. Int J Pharm; 397(1-2):50–58.

Norouzi M, Shabani I, Ahvaz HH, Soleimani M (2015). **PLGA/gelatin hybrid nanofibrous scaffolds encapsulating EGF for skin regeneration**. J Biomed Mater Res A; 103(7):2225-35. doi: 10.1002/jbm.a.35355.

Pant B, Park M, Park SJ (2019). **Drug Delivery Applications of Core-Sheath Nanofibers Prepared by Coaxial Electrospinning: A Review. Pharmaceutics**; 11(7):305. doi: 10.3390/pharmaceutics11070305.

Patel S, Kurpinski K, Quigley R, *et al*. (2007). **Bioactive nanofibers: synergistic effects of nanotopography and chemical signaling on cell guidance**. Nano Lett; 7(7):2122-8. doi: 10.1021/nl071182z.

Peh P, Lim NS, Blocki A, *et al*. (2015). **Simultaneous Delivery of Highly Diverse Bioactive Compounds from Blend Electrospun Fibers for Skin Wound Healing**. Bioconjug Chem; 26(7):1348-58. doi: 10.1021/acs.bioconjchem.5b00123.

Pelipenko J, Kristl J, Rošic R, Baumgartner S, Kocbek P (2012). **Interfacial rheology: an overview of measuring techniques and its role in dispersions and electrospinning**. Acta Pharm; 62(2):123-40. doi: 10.2478/v10007-012-0018-x.

Pelipenko J, Kocbek P, Govedarica B, Rošic R, Baumgartner S, Kristl J (2013a). **The topography of electrospun nanofibers and its impact on the growth and mobility of keratinocytes.** Eur J Pharm Biopharm; 84(2):401-11. doi: 10.1016/j.ejpb.2012.09.009.

Pelipenko J, Kristl J, Jankovic B, Baumgartner S, Kocbek P (2013b). **The impact of relative humidity during electrospinning on the morphology and mechanical properties of nanofibers.** Int J Pharm; 456:125–134.

Pelipenko J, Kocbek P, Kristl J (2015a). **Critical attributes of nanofibers: preparation, drug loading, and tissue regeneration**. Int J Pharm; 484(1-2):57-74. doi: 10.1016/j.ijpharm.2015.02.043.

Pelipenko J, Kocbek P, Kristl J (2015b). **Nanofiber diameter as a critical parameter affecting skin cell response**. Eur J Pharm Sci; 66:29-35. doi: 10.1016/j.ejps.2014.09.022.

Persano L, Camposeo A, Tekmen C, Pisignano D (2013). **Industrial upscaling of electrospinning and applications of polymer nanofibers: a review**. Macromol Mater Eng; 298:504–520.

Pham QP, Sharma U, Mikos AG (2006). Electrospinning of polymeric nanofibers for tissue engineering applications: a review. Tissue Eng; 12(5):1197-211. doi: 10.1089/ten.2006.12.1197.

Pinho ED, Martins A, Araujo JV, Reis RL, Neves NM (2009). **Degradable particulate composite reinforced with nanofibers for biomedical applications**. Acta Biomater; 5:1104–1114.

Quatresooz P, Kharfi M, Paquet P, Vroome V, Cauwenbergh G, Piérard GE (2006). **Healing effect of ketanserin on chronic leg ulcers in patients with diabetes.** J Eur Acad Dermatol Venereol; 20(3):277-81. doi: 10.1111/j.1468-3083.2006.01422.x.

Ranganath SH and Wang CH (2008). **Biodegradable microfiber implants delivering paclitaxel for post-surgical chemotherapy against malignant glioma**. Biomaterials; 29(20):2996-3003. doi: 10.1016/j.biomaterials.2008.04.002.

Reneker DH and Chun I (1996). **Nanometre diameter fibres of polymer, produced by electrospinning**. Nanotechnology; 7(3):216.

Reneker DH, Yarin AL, Fong H, Koombhongse S (2000). **Bending instability of electrically charged liquid jets of polymer solutions in electrospinning**. J Appl Phys; 87:4531–4547.

Rošic R, Pelipenko J, Kocbek P, Baumgartner S, Bešter-Rogac M, Kristl J (2012). **The role of rheology of polymer solutions in predicting nanofiber formation by electrospinning**. Eur Polym J; 48(8):1374–1384.

Rošic R, Kocbek P, Pelipenko J, Kristl J, Baumgartner S (2013). **Nanofibers and their biomedical use**. Acta Pharm; 63(3):295-304. doi: 10.2478/acph-2013-0024.

Sill TJ, von Recum HA. (2008) **Electrospinning: applications in drug delivery and tissue engineering.** Biomaterials ;29(13):1989-2006. doi: 10.1016/j.biomaterials.2008.01.011. Epub 2008 Feb 20.

Singh B, Garg T, Goyal AK, Rath G (2016). **Development, optimization, and characterization of polymeric electrospun nanofiber: a new attempt in sublingual delivery of nicorandil for the management of angina pectoris**. Artif Cells Nanomed Biotechnol; 44(6):1498-507. doi: 10.3109/21691401.2015.1052472.

Son WK, Youk JH, Lee TS, Park WH (2004). **The effects of solution properties and polyelectrolyte on electrospinning of ultrafine poly(ethylene oxide) fibers**. Polymer; 45:2959–2966.

Son YJ, Kim WJ, Yoo HS (2014). **Therapeutic applications of electrospun nanofibers for drug delivery systems.** Arch Pharm Res; 37(1):69-78. doi: 10.1007/s12272-013-0284-2.

Song B, Wu C, Chang J (2012) **Controllable delivery of hydrophilic and hydrophobic drugs from electrospun poly(lactic-co-glycolic acid)/mesoporous silica nanoparticles composite mats.** J Biomed Mater Res B Appl Biomater. 2012 Nov;100(8):2178-86. doi: 10.1002/jbm.b.32785. Epub

Sulejczak D, Andrychowski J, Kowalczyk T, Nakielski P, Frontczak-Baniewicz M, Kowalewski T. (2014) **Electrospun nanofiber mat as a protector against the consequences of brain injury.** Folia Neuropathol. ;52(1):56-69. doi: 10.5114/fn.2014.41744.

Szentivanyi A, Chakradeo T, Zernetsch H, Glasmacher B. (2011) **Electrospun cellular microenvironments: Understanding controlled release and scaffold structure.** Adv Drug Deliv Rev. ;63(4-5):209-20. doi: 10.1016/j.addr.2010.12.002. Epub

Thakkar S, Misra M. (2017) **Electrospun polymeric nanofibers: New horizons in drug delivery.** Eur J Pharm Sci ;107:148-167. doi: 10.1016/j.ejps.2017.07.001. Epub 2017 Jul 8.

Thomas R, Soumya KR, Mathew J, Radhakrishnan EK (2015). **Inhibitory effect of silver nanoparticle fabricated urinary catheter on colonization efficiency of Coagulase Negative Staphylococci**. J Photochem Photobiol; 149:68-77. doi: 10.1016/j.jphotobiol.2015.04.034.

Tian F, Hosseinkhani H, Hosseinkhani M, Khademhosseini A, Yokoyama Y, Estrada GG, Kobayashi H. (2008) **Quantitative analysis of cell adhesion on aligned micro- and nanofibers.** J Biomed Mater Res A ;84(2):291-9. doi: 10.1002/jbm.a.31304.

Tripatanasuwan S, Zhong Z, Reneker DH (2007). **Effect of evaporation and solidification of the charged jet in electrospinning of poly(ethylene oxide) aqueous solution.** Polymer 48, 5742–5746.

Tutak W, Sarkar S, Lin-Gibson S, Farooque TM, Jyotsnendu G, Wang D, *et al* (2013) **The support of bone marrow stromal cell differentiation by airbrushed nanofiber scaffolds**. Biomaterials ;34(10):2389-98. doi: 10.1016/j.biomaterials.2012.12.020. Epub

Unalan I, Endlein SJ, Slavik B, Buettner A, Goldmann WH, Detsch R, *et al* (2019) **Evaluation of Electrospun Poly(ε-Caprolactone)/Gelatin Nanofiber Mats Containing Clove Essential Oil for Antibacterial Wound Dressing. Pharmaceutics**.;11(11):570. doi: 10.3390/pharmaceutics11110570.

Veleirinho B, Rei MF, Lopes-Da-Silva JA (2008). **Solvent and concentration effects on the properties of electrospun poly(ethylene terephthalate) nanofiber mats.** J. Polym. Sci. Part B: Polym. Phys. 46, 460–471.

Wang HS, Fu GD, Li XS. (2009) **Functional polymeric nanofibers from electrospinning.** Recent Pat Nanotechnol. ;3(1):21-31. doi: 10.2174/187221009787003285.

Wang J, An Q, Li D, Wu T, Chen W, Sun B, *et al* (2015) **Heparin and Vascular Endothelial Growth Factor Loaded Poly(L-lactide-co-caprolactone) Nanofiber Covered Stent-Graft for Aneurysm Treatment.** J Biomed Nanotechnol. ;11(11):1947-60. doi: 10.1166/jbn.2015.2138.

Wang Z, Qian Y, Li L, Pan L, Njunge LW, Dong L, Yang L. (2016) **Evaluation of emulsion electrospun polycaprolactone/hyaluronan/epidermal growth factor nanofibrous scaffolds for wound healing.** J Biomater Appl. 2016 Jan;30(6):686-98. doi: 10.1177/0885328215586907. Epub 2015 May 26.

Williams GR, Chatterton NP, Nazir T, Yu DG, Zhu LM, Branford-White CJ (2012) **Electrospun nanofibers in drug delivery: recent developments and perspectives**. Ther Deliv. 2012 Apr;3(4):515-33. doi: 10.4155/tde.12.17. PMID: 22834080.

Woo CH, Choi YC, Choi JS, Lee HY, Cho YW (2015). **A bilayer composite composed of TiO2-incorporated electrospun chitosan membrane and human extracellular matrix sheet as a wound dressing.** J Biomater Sci Polym Ed; 26(13):841-54. doi: 10.1080/09205063.2015.1061349.

Xie J, Wang CH. (2006) **Electrospun micro- and nanofibers for sustained delivery of paclitaxel to treat C6 glioma in vitro**. Pharm Res. ;23(8):1817-26. doi: 10.1007/s11095-006-9036-z.

Xie J, Tan RS, Wang CH (2008). **Biodegradable microparticles and fiber fabrics for sustained delivery of cisplatin to treat C6 glioma in vitro**. J Biomed Mater Res A; 85(4):897-908. doi: 10.1002/jbm.a.31499.

Xu J, et al., (2011) **Controlled dual release of hydrophobic and hydrophilic drugs from electrospun poly (l-lactic acid) fiber mats loaded with chitosan microspheres**, Mater. Lett. 65 (17) 2800e2803.

Xu L, Sheybani N, Ren S, Bowlin GL, Yeudall WA, Yang H. (2015**) Semi-interpenetrating network (sIPN) co-electrospun gelatin/insulin fiber formulation for transbuccal insulin delivery.** Pharm Res.;32(1):275-85. doi: 10.1007/s11095-014-1461-9. Epub 2014 Jul 17.

Xu X, Chen X, Ma P, Wang X, Jing X. (2008) **The release behavior of doxorubicin hydrochloride from medicated fibers prepared by emulsion-electrospinning**. Eur J Pharm Biopharm.;70(1):165-70. doi: 10.1016/j.ejpb.2008.03.010. Epub 2008 Mar 28.

Xu X, Chen X, Wang Z, Jing X. (2009) **Ultrafine PEG-PLA fibers loaded with both paclitaxel and doxorubicin hydrochloride and their in vitro cytotoxicity.** Eur J Pharm Biopharm. ;72(1):18-25. doi: 10.1016/j.ejpb.2008.10.015. Epub 2008 Nov 6.

Xue J, Wu T, Dai Y, Xia, Y. (2019) **Electrospinning and Electrospun Nanofibers: Methods, Materials, and Applications.** Chem. Rev. 2019, 119, 5298–5415.

Yang C, Wu X, Zhao Y, Xu L, Wei S, (2011) **Nanofibrous scaffold prepared by electrospinning of poly(vinyl alcohol)/gelatin aqueous solutions**. J. Appl. Polym. Sci. 121, 3047–3055.

Yang F, Murugan R, Wang S, Ramakrishna S. (2005) **Electrospinning of nano/micro scale poly(L-lactic acid) aligned fibers and their potential in neural tissue engineering.** Biomaterials.;26(15):2603-10. doi: 10.1016/j.biomaterials.2004.06.051.

Yang Y, Xia T, Zhi W, Wei L, Weng J, Zhang C, *et al* (2011). **Promotion of skin regeneration in diabetic rats by electrospun core-sheath fibers loaded with basic fibroblast growth factor.** Biomaterials. ;32(18):4243-54. doi: 10.1016/j.biomaterials.2011.02.042. Epub 2011 Mar 12. PMID: 21402405.

Yarin, A.L., Zussman, E., (2004). **Upward needleless electrospinning of multiple nanofibers.** Polymer 45, 2977–2980.

Yu DG, White K, Yang JH, Wang X, Qian W, Li Y, (2012). **PVP nanofibers prepared using co-axial electrospinning with salt solution as sheath fluid.** Mater. Lett. 67, 78–80.

Yu DG, Chian W, Wang X, Li XY, Li Y, Liao YZ, (2013a). **Linear drug release membrane prepared by a modified coaxial electrospinning process.** J. Membr. Sci. 428, 150–156.

Yu DG, Chian W, Wang X, Li XY, Li Y, Liao YZ, (2013b). **Electrospun biphasic drug release polyvinylpyrrolidone/ethyl cellulose core/sheath nanofibers**. Acta Biomater. 9, 5665–5672.

Zandi N, Lotfi R, Tamjid E, Shokrgozar MA, Simchi A. (2020) **Core-sheath gelatin based electrospun nanofibers for dual delivery release of biomolecules and therapeutics.** Mater Sci Eng C Mater Biol Appl. 2020 Mar;108:110432. doi: 10.1016/j.msec.2019.110432. Epub 2019 Nov 15.

Zeng J, Haoqing H, Schaper A, Wendorff Joachim, H, Greiner A, (2003) **Poly-Llactide nanofibers by electrospinning–Influence of solution viscosity and electrical conductivity on fiber diameter and fiber morphology.** e-Polymers 102.

Zhang X, Gao X, Jiang L, Zhang X, Qin J. (2011) **Nanofiber-modified surface directed cell migration and orientation in microsystem.** Biomicrofluidics. 2011 Sep;5(3):32007-3200710. doi: 10.1063/1.3614457. Epub 2011 Sep 20. PMID: 22662030;

Zhang, C.-L., Yu, S.-H., (2014) **Nanoparticles meet electrospinning: recent advances and future prospects.** Chem. Soc. Rev. 43, 4423–4448.

Zhao Z, Li J, Yuan X, Li X, Zhang Z, Sheng J, (2005). **Preparation and properties of electrospun poly(vinylidene fluoride) membranes.** J. Appl. Polym. Sci. 97, 466.

Zhu J, Lin F, Brown DA, Clark RAF (2014). **A fibronectin peptide redirects PDGF-BB/PDGFR complexes to macropinocytosis-like internalization and augments PDGF-BB survival signals**. J Invest Dermatol; 134(4):921-929. doi: 10.1038/jid.2013.463.